<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults - Chakupurakal, G - 2023 | Cochrane Library</title> <meta content="Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults - Chakupurakal, G - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009159.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults - Chakupurakal, G - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009159.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009159.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults" name="citation_title"/> <meta content="Geothy Chakupurakal" name="citation_author"/> <meta content="gpurakal@yahoo.com" name="citation_author_email"/> <meta content="Paul Freudenberger" name="citation_author"/> <meta content="CGS Clinical Guideline Services GmbH" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Hans Ahr" name="citation_author"/> <meta content="Rheinland Klinikum" name="citation_author_institution"/> <meta content="Sebastian Theurich" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009159.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009159.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009159.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009159.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antilymphocyte Serum [therapeutic use]; Bone Marrow Transplantation; *Bronchiolitis Obliterans Syndrome; *Graft vs Host Disease [prevention &amp; control]; *Hematopoietic Stem Cell Transplantation [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009159.pub3&amp;doi=10.1002/14651858.CD009159.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009159\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009159\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ms","hr","fa","id","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009159.pub3",title:"Polyclonal anti\\u2010thymocyte globulins for the prophylaxis of graft\\u2010versus\\u2010host disease after allogeneic stem cell or bone marrow transplantation in adults",firstPublishedDate:"Jun 21, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009159.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009159.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009159.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009159.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009159.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009159.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009159.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009159.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009159.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009159.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1173 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009159.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/appendices#CD009159-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/supinfo/CD009159-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/supinfo/CD009159-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#CD009159-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Geothy Chakupurakal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#CD009159-cr-0005">Paul Freudenberger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#CD009159-cr-0006">Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#CD009159-cr-0007">Hans Ahr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information#CD009159-cr-0008">Sebastian Theurich</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information/en#CD009159-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009159.pub3">https://doi.org/10.1002/14651858.CD009159.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009159-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009159-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009159-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009159-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009159-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009159-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009159-abs-0001" lang="en"> <section id="CD009159-sec-0001"> <h3 class="title" id="CD009159-sec-0001">Background</h3> <p>Allogeneic haematopoietic stem cell transplantation (SCT) is an established treatment for many malignant and non‐malignant haematological disorders. Graft‐versus‐host disease (GVHD), a condition frequently occurring after an allogeneic SCT, is the result of host tissues being attacked by donor immune cells. It affects more than half of the patients after transplant either as acute and or chronic GVHD. One strategy for the prevention of GVHD is the administration of anti‐thymocyte globulins (ATGs), a set of polyclonal antibodies directed against a variety of immune cell epitopes, leading to immunosuppression and immunomodulation. </p> </section> <section id="CD009159-sec-0002"> <h3 class="title" id="CD009159-sec-0002">Objectives</h3> <p>To assess the effect of ATG used for the prevention of GVHD in patients undergoing allogeneic SCT with regard to overall survival, incidence and severity of acute and chronic GVHD, incidence of relapse, non‐relapse mortality, graft failure and adverse events. </p> </section> <section id="CD009159-sec-0003"> <h3 class="title" id="CD009159-sec-0003">Search methods</h3> <p>For this update we searched the CENTRAL, MEDLINE, Embase, trial registers and conference proceedings on the 18th November 2022 along with reference checking and contacting study authors to identify additional studies. </p> <p>We did not apply language restrictions.</p> </section> <section id="CD009159-sec-0004"> <h3 class="title" id="CD009159-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) investigating the impact of ATG on GVHD prophylaxis in adults suffering from haematological diseases and undergoing allogeneic SCT. The selection criteria were modified from the previous version of this review. Paediatric studies and studies where patients aged &lt; 18 years constituted more than 20 % of the total number were excluded. Treatment arms had to differ only in the addition of ATG to the standard GVHD prophylaxis regimen. </p> </section> <section id="CD009159-sec-0005"> <h3 class="title" id="CD009159-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by the Cochrane Collaboration for data collection, extraction and analyses. </p> </section> <section id="CD009159-sec-0006"> <h3 class="title" id="CD009159-sec-0006">Main results</h3> <p>For this update we included seven new RCTs, leading to a total of ten studies investigating 1413 participants. All patients had a haematological condition which warranted an allogeneic SCT. The risk of bias was estimated as low for seven and unclear for three studies. </p> <p>ATG probably has little or no influence on overall survival (HR (hazard ratio) 0.93 (95 % confidence interval (CI) 0.77 to 1.13, nine studies, n = 1249, moderate‐certainty evidence)). Estimated absolute effect: 430 surviving people per 1000 people not receiving ATG compared to 456 people surviving per 1000 people receiving the intervention (95 % CI 385 to 522 per 1000 people). </p> <p>ATG results in a reduction in acute GVHD II to IV with relative risk (RR) 0.68 (95 % CI 0.60 to 0.79, 10 studies, n = 1413, high‐certainty evidence). Estimated absolute effect: 418 acute GVHD II to IV per 1000 people not receiving ATG compared to 285 per 1000 people receiving the intervention (95 % CI 251 to 331 per 1000 people). Addition of ATG results in a reduction of overall chronic GvHD with a RR of 0.53 (95 % CI 0.45 to 0.61, eight studies, n = 1273, high‐certainty evidence). Estimated absolute effect: 506 chronic GVHD per 1000 people not receiving ATG compared to 268 per 1000 people receiving the intervention (95 % CI 228 to 369 per 1000 people). Further data on severe acute GVHD and extensive chronic GVHD are available in the manuscript. </p> <p>ATG probably slightly increases the incidence of relapse with a RR of 1.21 (95 % CI 0.99 to 1.49, eight studies,  n =1315, moderate‐certainty evidence).<br/>Non relapse mortality is probably slightly or not affected by ATG with an HR of 0.86 (95 % CI 0.67 to 1.11, nine studies, n=1370, moderate‐certainty evidence).   </p> <p>ATG prophylaxis may result in no increase in graft failure with a RR of 1.55 (95 % CI 0.54 to 4.44, eight studies, n = 1240, low‐certainty evidence).  </p> <p>Adverse events could not be analysed due to the serious heterogeneity in the reporting between the studies, which limited comparability (moderate‐certainty evidence) and are reported in a descriptive manner.   </p> <p>Subgroup analyses on ATG types, doses and donor type are available in the manuscript.</p> </section> <section id="CD009159-sec-0007"> <h3 class="title" id="CD009159-sec-0007">Authors' conclusions</h3> <p>This systematic review suggests that the addition of ATG during allogeneic SCT probably has little or no influence on overall survival. ATG results in a reduction in the incidence and severity of acute and chronic GvHD. ATG intervention probably slightly increases the incidence of relapse and probably does not affect the non relapse mortality. Graft failure may not be affected by ATG prophylaxis. Analysis of data on adverse events was reported in a narrative manner. A limitation for the analysis was the imprecision in reporting between the studies thereby reducing the confidence in the certainty of evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009159-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009159-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009159-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009159-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009159-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009159-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009159-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD009159-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD009159-abs-0012">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009159-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009159-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009159-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009159-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009159-abs-0002" lang="en"> <h3>Anti‐thymocyte globulins for the prevention of graft‐versus‐host disease in patients receiving a foreign stem cell transplantation </h3> <p> </p> <p><b>What is allogeneic stem cell transplantation and graft‐versus‐host‐disease?</b> </p> <p>Allogeneic stem cell transplantation (SCT) is the transfer of foreign i.e. not one's own stem cells, from a donor to the patient (recipient). It is a potentially curative therapeutic option for a variety of blood‐related diseases. More than 8000 allogeneic SCT are conducted in the USA alone every year since 2015. In 2016, the World bone marrow registry recorded around 29,000 allogeneic SCT worldwide.<br/>Even though the donor and the recipient are compatible, donor cells could recognise tissues of the recipient ('the host') as foreign, resulting in an inflammation called 'graft‐versus‐host‐disease' (GVHD). In 2021 The centre for International blood and marrow transplant research (CIBMTR) reported recurrence of disease as the most important cause of death (50%) followed by death due to causes other than the underlying diseases.  GVHD is an important factor contributing to complications resulting in the reduced quality of life and death of these patients after an allogeneic SCT.  </p> <p><b>What are anti‐thymocyte globulins?</b> </p> <p>Host immune cells can be eliminated by the addition of antibodies directed against them, such as with anti‐thymocyte globulins (ATG).  </p> <p><b>Why did we do this review?</b> </p> <p>ATG has been used for decades to reduce the incidence and severity of GVHD, but the effectivity of this treatment modality still remains a matter of dispute. <br/>The aim of this systematic review was to update our previous review and analyse the advantages and disadvantages of the use of ATG for GVHD prophylaxis in an allogeneic SCT. We aimed to identify the role of this treatment modality in this setting. </p> <p><b>What did we do? </b> </p> <p>We searched for randomised controlled trials that compared ATG with placebo which analysed the following outcomes: Overall survival, incidence and severity of acute and chronic GVHD, incidence of relapse, non‐relapse mortality, graft failure, adverse events, infections and quality of life.<br/>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence was updated on 18<sup>th</sup> November 2022. </p> <p><b>What did we find?</b> </p> <p>Ten randomised controlled trials comprising 1413 patients were identified for this review.<br/>The studies were conducted in different parts of the world with 263 patients in the biggest study and 43 in the smallest study. Four studies with a total of 465 patients were conducted in Europe whereas a total of 450 patients were recruited in two studies conducted in North America, Australia and Canada. 498 Chinese patients were studied in four trials, three of which were in single centres and the fourth trial had 23 recruiting centres throughout China. </p> <p><b>What are our results? </b> </p> <p>Our analyses show that a prophylactic use of ATG probably has little or no influence on the overall survival of patients who receive an allogeneic SCT.  </p> <p>ATG prophylaxis results in a reduction in the occurrence and severity of acute and chronic GvHD.  <br/>The risk of recurrence of disease after transplantation is probably slightly increased, though ATG prophylaxis probably has little or no effect on the chance of dying from causes other than the underlying disease.<br/>Transplant failure may not be affected by the intervention. <br/>The effect of ATG on adverse events after SCTwas reported in a descriptive manner.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have moderate confidence in our finding that ATG has little or no influence on overall survival. We have high confidence in our finding that ATG reduces acute and chronic GVHD. We have moderate confidence in our finding that ATG probably slightly increases the incidence of relapse and probably does not affect non‐relapse mortality. The addition of ATG may result in no increase in graft failure, but our confidence in the finding is low. All the aforementioned limitations in the certainty of evidence are caused by serious or very serious imprecision. </p> <p>We have moderate confidence in our analysis on adverse events, although we report in a narrative manner, due to heterogeneity in the reported outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009159-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009159-sec-0104"></div> <h3 class="title" id="CD009159-sec-0105">Implications for practice</h3> <section id="CD009159-sec-0105"> <p> <ul id="CD009159-list-0024"> <li> <p>Our meta‐analysis shows probably little to no difference that the addition of ATG impacted overall survival. </p> </li> <li> <p>There is evidence that the addition of anti‐thymocyte globulins (ATG) to the standard prophylaxis regimen of GvHD reduces the incidence and severity of acute and chronic graft‐versus‐host disease (GvHD).   </p> </li> <li> <p>The incidence of relapse probably increases slightly, but non‐relapse mortality is slightly or not at all affected by ATG use.  </p> </li> <li> <p>ATG may result in no increased number of graft failures.</p> </li> <li> <p>Due to lack of comparable data, an analysis of the data on adverse events was not possible.  </p> </li> <li> <p>Newer therapeutic options have improved the GVHD associated morbidity and mortality. The slight increase in relapse reduces the appeal of ATG as an option for GVHD prophylaxis in an allogeneic stem cell transplantation (SCT) given the availability of alternative ways. </p> </li> </ul> </p> </section> <h3 class="title" id="CD009159-sec-0106">Implications for research</h3> <section id="CD009159-sec-0106"> <p>Long‐term follow‐up data on patients studied in the reviewed randomised controlled trials (RCTs) are needed to analyse the impact of adding ATG to standard GvHD prophylaxis on overall survival, incidence of relapse, incidence of infections and non‐relapse mortality. Standardised reporting would have been helpful to pool data, for example incidence of infection or relapse. As each study had different median follow‐ups the data on the subgroups were variable. Only two studies reported on the quality of life of the patients, and most did not specify the adverse events. Standardised reporting on quality of life and adverse effect would also be helpful ‐ as these are key considerations in the patient's decision‐making process </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009159-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009159-sec-0008"></div> <div class="table" id="CD009159-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients after allogeneic stem cell or bone marrow transplantation<br/><b>Intervention:</b> ATG </p> <p><b>Control Intervention</b>: No ATG </p> <p><b>Setting</b>: inpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No ATG</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ATG (95%CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Overall survival</b> (at 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low survival**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>HR 0.93 </b><br/>(0.77 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>1249<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/>(385 to 522) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High survival **</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>737 per 1000</b><br/>(690 to 777) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute GVHD II to IV </b><br/>(90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/>(251 to 331) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b><br/>(0.60 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1413<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall Chronic GVHD </b><br/>(up to 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>506 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/>(228 to 309) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/>(0.45 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1273<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small study (Study weight &lt;5%) by <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a><i> </i>was removed due to hetero‐geneity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of relapse</b> </p> <p>(up to 36 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(197 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21 </b><br/>(0.99 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1315<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Non‐relapse mortality</b> (at 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low ***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.67 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1370</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1000</b> (75 to 121) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High ***</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>449 per 1000</b> </p> <p>(371 to 537)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft failure</b> (during study) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> <p>(4 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.55</b> </p> <p>(0.54 to 4.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1240</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse Events</b> (during study) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>3 Studies reported no differences in AE between groups.</p> <p>1 study found similar SAEs between groups</p> <p>1 study reported a much higher incidence of AEs and SAEs in the ATG group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>543 <br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A narrative summary approach was chosen due to differences in reporting and the data could not be analysed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> represents the mean baseline risk from the studies in the meta‐analysis. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>** /*** For time‐to event analyses we used the lowest and highest observed values in the included studies to calculate ranges for the illustrative comparative risks. These illustrate the discrepancies in risk for varying populations.<br/>** Lowest observed by <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; highest observed by <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>. </p> <p>*** Lowest observed by <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; highest observed by <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to serious imprecision and 95% confidence interval including both potential benefit and harm.<br/><sup>2</sup> Downgraded two points due to very serious imprecision and 95% confidence interval including both potential benefit and harm.<br/><sup>3</sup> Downgraded one point due to serious heterogeneity in the reporting of adverse events between the studies, which limited comparability. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009159-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009159-sec-0009"></div> <section id="CD009159-sec-0010"> <h3 class="title" id="CD009159-sec-0010">Haematopoietic stem cell transplantation</h3> <p>Allogeneic stem cell transplantation (SCT) is an established treatment for many malignant and non‐malignant haematological disorders. The EBMT survey in 2018 reported that approximately 20,000 allogeneic SCT are performed in Europe per year (<a href="./references#CD009159-bbs2-0071" title="PasswegJR , BaldomeroH , ChabannonC , BasakGW , CorbaciogluS , DuarteR , et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. Bone Marrow Transplantation2020;55(8):1604-13.">Passweg 2020</a>). More than 8000 allogeneic SCT are conducted in the USA alone every year since 2015 (<a href="./references#CD009159-bbs2-0042" title="AulettaJJ , KouJ , ChenM , ShawBE . Current use and outcome of hematopoietic stem cell transplantation. CIBMTR US summary slides2021.">CIBMTR  US summary slides</a>). In 2016, the World bone marrow registry recorded around 29,000 allogeneic SCT worldwide (<a href="./references#CD009159-bbs2-0066" title="NiederwieserD , BaldomeroH , BazuayeN , BuppC , ChaudhriN , CorbaciogluS , et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica 2022 May 1;1:1045-53. [DOI: 10.3324/haematol.2021.279189] [PMID: 34382386]">Niederwieser 2022</a>). During SCT, haematopoietic stem cells are transferred from a healthy donor to a recipient to act as a substitute for deficient or malignant cells. Sources of stem cells include peripheral blood, bone marrow and umbilical cord blood. </p> <p>Prior to transplantation, a conditioning regimen establishes eradication of malignant or malfunctioning cells as well as providing adequate space for engraftment of donor cells. There are three types of conditioning regimens‐myeloablative (MA), non‐myeloablative (NMA) and reduced intensity (RIC) conditioning. MA conditioning consists of high‐dose chemotherapy with or without total body irradiation (TBI) which results in the ablation of stem cells and hence, a haematopoietic recovery without SCT is not possible. NMA conditioning regimens cause minimal cytopenia and thus stem cell support is not mandatory. RIC regimens do not fit the criteria for MA or NMA. They need to be administered with stem cell support though The associated cytopenias after a RIC may not be irreversible, but can be of unreliable duration. Hence, stem cell support following RIC is mandatory (<a href="./references#CD009159-bbs2-0039" title="BacigalupoA , BallenK , RizzoD , GiraltS , LazarusH , HoV , et al. Defining the intensity of conditioning regimens: working definitions. Biology of Blood and Marrow Transplant 2009 Dec;15:1628-33. [DOI: 10.1016/j.bbmt.2009.07.004]">Bacigalupo 2009</a>).  The reduced doses of chemotherapy and or radiotherapy make the procedure less toxic and thereby the possibility to offer this procedure to patients with advanced age or co‐morbidities (<a href="./references#CD009159-bbs2-0052" title="GyurkoczaB , SandmaierBM . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood2014;124(3):344-53.">Gyurkocza 2014</a>). </p> <p>Important complications of an allogeneic SCT include conditioning‐induced toxicity, graft‐failure, infections and graft‐versus‐host disease (GVHD), and are responsible for a significant mortality and morbidity following the transplant (<a href="./references#CD009159-bbs2-0047" title="GhimireS , WeberD , MavinE , WangXN , DickinsonAM , HollerE . Pathophysiology of GvHD and Other HSCT-Related Major Complications. Frontiers in Immunology2017;8:79.">Ghimire 2017</a>). In 2021, the centre for International blood and marrow transplant research (CIBMTR) reported recurrence of disease as the most important cause of death (50 %) followed by death due to causes other than the underlying diseases (<a href="./references#CD009159-bbs2-0042" title="AulettaJJ , KouJ , ChenM , ShawBE . Current use and outcome of hematopoietic stem cell transplantation. CIBMTR US summary slides2021.">CIBMTR  US summary slides</a>). Graft failure is another important complication of SCT with an incidence between 3% to 5 %, sibling transplants have a lower incidence of graft failure in comparison to matched unrelated transplants (<a href="./references#CD009159-bbs2-0067" title="OlssonRF , LoganBR , ChaudhuryS , ZhuX , AkpekG , BolwellBJ , et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.. Leukaemia 2015 Aug;29:1754-62.">Olsson 2015</a>; <a href="./references#CD009159-bbs2-0081" title="ValcaercelD , SuredaA . Graft failure. In: EBMT Handbook 2019. Springer, 2019. [DOI: https://doi.org/10.1007/978-3-030-02278-5_41]">Valcaercel 2019</a>). </p> </section> <section id="CD009159-sec-0011"> <h3 class="title" id="CD009159-sec-0011">Description of the condition</h3> <section id="CD009159-sec-0012"> <h4 class="title">Graft‐versus‐host disease</h4> <p>GVHD is a condition in which host tissues are attacked by alloreactive donor immune cells. Traditionally, GVHD is divided into acute and chronic forms, depending on whether the onset is before or after day 100 post‐transplantation (<a href="./references#CD009159-bbs2-0048" title="GlucksbergH , StorbR , FeferA , BucknerC , NeimanP , CliftR . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974 October;18(4):295-304.">Glucksberg 1974</a>). In clinical practice, however, either form can occur outside this arbitrary cut‐off point and the form can be better distinguished by symptoms rather than time of occurrence. The current National Institutes of Health (NIH) consensus criteria also include an overlap syndrome highlighting the difficulties in diagnosis of this condition (<a href="./references#CD009159-bbs2-0056" title="JagasiaMH , GreinixHT , AroraM , WilliamsKM , WolffD , CowenEW , et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation2015;21(3):389-401.e1.">Jagasia 2015</a>). </p> <p>The inflammation and immune dysregulation following the transfer of the haematopoietic system of a non‐genetic identical donor into a recipient may result in GvHD. The pathophysiology is explained in a three‐step model. The first step is the activation of antigen‐presenting cells (APC) as a result of tissue damage caused by underlying disease and conditioning toxicity. Secondly, donor T‐cells are activated by stimulatory cytokines and the response to APCs. Finally, effector cells such as cytotoxic T‐cells and natural killer cells in combination with inflammatory cytokines cause further damage (<a href="./references#CD009159-bbs2-0043" title="FerraraJLM , LevineJE , ReddyP , HollerE . Graft-versus-host disease. Lancet 2009 May;373(9674):1550-61. [DOI: 10.1016/S0140-6736(09)60237-3]">Ferrara 2009</a>; <a href="./references#CD009159-bbs2-0068" title="PaczesnyS , HanauerD , SunY , ReddyP . New perspectives on the biology of acute GVHD. Bone Marrow Transplantation 2010 January;45(1):1-11. [DOI: 10.1038/bmt.2009.328]">Paczesny 2010</a>). Not all SCT recipients develop GVHD.  </p> <section id="CD009159-sec-0013"> <h5 class="title">Acute GVHD</h5> <p>Acute GvHD classified into groups I to IV by evaluating the percentage of skin involvement, bilirubin values and volume of diarrhoea (<a href="./references#CD009159-bbs2-0056" title="JagasiaMH , GreinixHT , AroraM , WilliamsKM , WolffD , CowenEW , et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation2015;21(3):389-401.e1.">Jagasia 2015</a>). The symptoms may be a rash which can be limited or generalised with varying degrees of severity, nausea, vomiting, diarrhoea and or jaundice. It affects approximately 60 % of patients who have received an allogeneic SCT. Severe grade III‐IV acute GVHD and chronic GVHD remains a significant cause of treatment‐related mortality (<a href="./references#CD009159-bbs2-0043" title="FerraraJLM , LevineJE , ReddyP , HollerE . Graft-versus-host disease. Lancet 2009 May;373(9674):1550-61. [DOI: 10.1016/S0140-6736(09)60237-3]">Ferrara 2009</a>, <a href="./references#CD009159-bbs2-0062" title="Martinez-CibrianN , ZeiserR , Perez-SimonJA . Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. Blood Reviews 2021 July;48:Epub. [EMBASE: 10.1016/j.blre.2020.100792]">Martinez‐Cibrian 2021</a>)<i>.</i> Risk factors for the development of acute GVHD include the type of donor and degree of mismatch, gender difference and cytomegalovirus (CMV) antigen status of donor and recipient (<a href="./references#CD009159-bbs2-0058" title="LeeSE , ChoBS , KimJH , YoonJH , ShinSH , YahngSA , et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplantation2013;48(4):587-92.">Lee 2013</a>). Standard prophylaxis of GVHD consists of immunosuppressive drugs, mostly a combination of a calcineurin inhibitor with methotrexate or mycophenolate mofetil (MMF) commenced prior to transplant. Other GVHD prophylaxis agents include tacrolimus, sirolimus and in vivo T‐cell depletion by the use of anti‐thymocyte globulins (ATG). The mainstay of treatment of GVHD is corticosteroids, and if needed other immune suppressive agents. Nevertheless, less than half of the patients achieve a complete response. The prolonged immune suppression resulting from the treatment leads to a variety of infectious complications increasing the post transplant morbidity and mortality (Jamil 2015; <a href="./references#CD009159-bbs2-0073" title="RamachandranV , KolliSS , StrowdLC . Review of graft-versus-host disease. Dermatologic Clinics2019;37(4):569-82.">Ramachandran 2019</a>). </p> </section> <section id="CD009159-sec-0014"> <h5 class="title">Chronic GVHD</h5> <p>Chronic GVHD presents with slower dynamics than the acute form and symptoms that resemble autoimmune diseases, including fibrosis caused by chronic inflammation of the skin and internal organs (<a href="./references#CD009159-bbs2-0064" title="MorenoDF , CidJ . Graft-versus-host disease. Medicina Clinica2019;152(1):22-8.">Moreno 2019</a>). Chronic GVHD is broadly divided into limited and extensive (<a href="./references#CD009159-bbs2-0056" title="JagasiaMH , GreinixHT , AroraM , WilliamsKM , WolffD , CowenEW , et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation2015;21(3):389-401.e1.">Jagasia 2015</a>, <a href="./references#CD009159-bbs2-0059" title="LeeSJ . Classification systems for chronic graft-versus-host disease. Blood2017;129(1):30-7.">Lee 2017</a>). The two forms are further divided based on organ involvement and severity. The symptoms vary from a rash to raised or discoloured areas or stiffening of the joints reducing the range of mobility. Nausea, vomiting, diarrhoea, abdominal pain or jaundice can also be  symptoms depending on the organ affected. On average, 50 % of SCT recipients develop chronic GVHD, but this ranges from 30 % to 80 % depending on risk factors (<a href="./references#CD009159-bbs2-0055" title="HorwitzME , SullivanKM . Chronic graft-versus-host disease. Blood 2006 January;20(1):15-27. [DOI: 10.1016/j.blre.2005.01.007]">Horwitz 2006</a>). An important risk factor for chronic GVHD is acute GVHD. Other risk factors include host donor compatibility, type and age of donor, type of transplantation and underlying disease status (<a href="./references#CD009159-bbs2-0044" title="Flowers ME InamotoY , CarpenterPA , LeeSJ , KiemHP , PetersdorfEW , et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood2011;117(11):3214-9.">Flowers 2011</a>). The 10‐year survival rate for mild chronic GVHD is approximately 80%, but decreases to less than 5% in patients with severe chronic GVHD. The GVHD‐related mortality can reach up to 12% and also cause significant morbidity, organ dysfunction, impair quality of life as well as lead to secondary malignancies (<a href="./references#CD009159-bbs2-0082" title="WingardJR , MajhailNS , BrazauskasR , WangZ , SobocinskiKA , JacobsohnD , et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology2011;29(16):2230-9.">Wingard 2011</a>). In the extensive form of chronic GVHD, intensive skin involvement and persisting thrombocytopenia are indicators for a poor prognosis (<a href="./references#CD009159-bbs2-0043" title="FerraraJLM , LevineJE , ReddyP , HollerE . Graft-versus-host disease. Lancet 2009 May;373(9674):1550-61. [DOI: 10.1016/S0140-6736(09)60237-3]">Ferrara 2009</a>; <a href="./references#CD009159-bbs2-0055" title="HorwitzME , SullivanKM . Chronic graft-versus-host disease. Blood 2006 January;20(1):15-27. [DOI: 10.1016/j.blre.2005.01.007]">Horwitz 2006</a>). The main stay treatment of chronic GVHD is systemic and or topical corticosteroids, with or without further immune suppressive agents. A number of other second‐line therapies have been studied, but no consensus has been reached on suitable substitutes or additional therapy that could help reduce the use of corticosteroids. Reducing corticosteroid use is of central importance because of the serious side effects and increased rate of infections. Mycophenolate mofetil and extracorporal photopheresis are the standard second‐line therapy options for steroid refractory GVHD (<a href="./references#CD009159-bbs2-0045" title="FlowersME , MartinPJ . How we treat chronic graft-versus-host disease. Blood2015;125(4):606-15.">Flowers 2015</a>; <a href="./references#CD009159-bbs2-0072" title="PenackO , MarchettiM , RuutuT , AljurfM , BacigalupoA , BonifaziF , et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.. Lancet Haematology 2020 Feb;7:e157-e167. [DOI: 10.1016/S2352-3026(19)30256-X]">Penack 2020</a>).  A novel agent which has changed the scene and been approved for treatment is Ruxolitinib, a Janus kinase inhibitor (<a href="./references#CD009159-bbs2-0083" title="ZeiserR , vonBubnoffN , ButlerJ , MohtyM , NiederwieserD , OrR , et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. New England Journal of Medicine 2020 May 7;382:1800-10. [DOI: 10.1056/NEJMoa1917635]">Zeiser 2020</a>; <a href="./references#CD009159-bbs2-0084" title="ZeiserR , PolverelliN , RamR , HashmiSK , ChakravertyR , MiddekeJM , et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. New England Journal of Medicine 2021 Jul;385:228-38. [DOI: 10.1056/NEJMoa2033122]">Zeiser 2021</a>). </p> </section> </section> </section> <section id="CD009159-sec-0015"> <h3 class="title" id="CD009159-sec-0015">Description of the intervention</h3> <p>ATG are an inhomogeneous group of polyclonal Immunoglobulin G (IgG) antibodies purified mainly from the serum of rabbits or horses that have been immunised with thymocytes or T‐cell lines (<a href="#CD009159-tbl-0002">Table 1</a>). Since the late 1970s, ATGs have been administered as part of conditioning therapy in order to reduce the incidence and severity of GVHD by in vivo T‐cell depletion. Over the years, the indication for the use of ATG has changed from a general application during allogeneic SCT towards situations of increased GVHD risks, such as grafts from unrelated or even mismatched donors. An important therapeutic role for ATG is in the management of severe aplastic anaemia prior to an allogeneic SCT (<a href="./references#CD009159-bbs2-0080" title="Tjon JM, LangemeijerSK , HalkesCJ . Anti thymocyte globulin-based treatment for acquired bone marrow failure in adults. Cells 2021 Oct 27;10:2905. [DOI: 10.3390/cells10112905]">TIjon 2021</a>). ATGs have also been used, although less successfully, as second‐line treatment for acute and chronic GVHD in corticosteroid‐refractory disease (<a href="./references#CD009159-bbs2-0033" title="AdmiraalR , BoelensJJ . Anti-thymocyte globulin for GVHD: one dose does not fit all. Lancet Haematology2020;7(7):e505.">Admiraal 2020</a>; <a href="./references#CD009159-bbs2-0076" title="SiddiquiS , CoxJ , HerzigR , PalaniyandiS , HildebrandtGC , MunkerR . Anti-thymocyte globulin in haematology: Recent developments. Indian Journal of Medical Research2019;150(3):221-7.">Siddiqui 2019</a>).  </p> <div class="table" id="CD009159-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used ATG preparations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ATG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Manufacturer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Host animal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunised with</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATGAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacia Upjohn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Horse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fresenius</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rabbit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Jurkat cell line</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lymphoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genzyme, formerly Mérieux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Horse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genzyme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rabbit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> </tbody> </table> </div> <section id="CD009159-sec-0016"> <h4 class="title">Adverse effects</h4> <p>Early adverse effects of ATG administration include fever, rash, cardiovascular and gastrointestinal dysfunction, serum sickness, haemolysis and thrombocytopenia. These occur in more than 80 % of the patients. ATG administration results in a prolonged severe lymphopenia, leading to an increased risk of infections especially virus reactivations such as Epstein‐Barr virus (EBV) and cytomegalovirus (CMV), and fungal infections as well as post transplant lymphoproliferative disorders (PTLD).  </p> </section> </section> <section id="CD009159-sec-0017"> <h3 class="title" id="CD009159-sec-0017">How the intervention might work</h3> <p>As GVHD is predominantly T‐cell mediated, T‐cell depletion by polyclonal or monoclonal T‐cell antibodies has been used as GVHD prophylaxis. ATG are polyclonal IgG antibodies, and can target and deplete not only single T‐cells but also B‐cells, NK‐cells and monocytes (<a href="./references#CD009159-bbs2-0051" title="GrüllichC , ZieglerC , FinkeJ . Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biology of Blood and Marrow Transplantation 2009 February;15(2):173-82.">Grüllich 2009</a>). They act mainly via direct cytotoxicity by binding T‐cell surface epitopes and also by complement dependent lysis (<a href="./references#CD009159-bbs2-0037" title="BacigalupoA . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplantation 2005 February;35(3):225-31. [DOI: 10.1038/sj.bmt.1704758]">Bacigalupo 2005</a>). This leads to T‐cell depletion in vivo. In vitro data demonstrate that an induction of regulatory T‐cells might also contribute to the immunoregulatory features of ATG (<a href="./references#CD009159-bbs2-0061" title="LopezM , ClarksonMR , AlbinM , SayeghMH , NajafianN . A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. Journal of the American Society of Nephrology 2006 October;17(10):2844-53.">Lopez 2006</a>). As a result of the T‐cell depletion they can bring about a reduction in the incidence and severity of acute and chronic GVHD. </p> </section> <section id="CD009159-sec-0018"> <h3 class="title" id="CD009159-sec-0018">Why it is important to do this review</h3> <p>Interpretation of the data from clinical trials on the impact of ATG prophylaxis on GVHD is somewhat controversial. It is difficult to compare the results from trials because of different dosages, administration schedules and ATG formulations used in the studies. Due to the differences of the manufacturing process, different ATG preparations have, in part, completely different targets and should be regarded as distinct drugs. </p> <p>Although a few reviews exist on the use of ATGs and their cellular mechanism of action, at the time point of publication of the first protocol for this systematic review, there was no meta‐analysis evaluating clinical randomised trials (<a href="./references#CD009159-bbs2-0037" title="BacigalupoA . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplantation 2005 February;35(3):225-31. [DOI: 10.1038/sj.bmt.1704758]">Bacigalupo 2005</a>; <a href="./references#CD009159-bbs2-0065" title="MohtyM . Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007 July;21(7):1387-94. [DOI: 10.1038/sj.leu.2404683]">Mothy 2007</a>). Several types of ATG from different suppliers (mainly Fresenius or Genzyme) have been used for decades for the prophylaxis of GVHD. The results seem to be contradictory, not only with regard to the incidence of GVHD, but also the early and late effects due to the resulting immunosuppression (<a href="./references#CD009159-bbs2-0037" title="BacigalupoA . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplantation 2005 February;35(3):225-31. [DOI: 10.1038/sj.bmt.1704758]">Bacigalupo 2005</a>; <a href="./references#CD009159-bbs2-0043" title="FerraraJLM , LevineJE , ReddyP , HollerE . Graft-versus-host disease. Lancet 2009 May;373(9674):1550-61. [DOI: 10.1016/S0140-6736(09)60237-3]">Ferrara 2009</a>). Therefore, in this systematic review we focus on the impact of ATG for the prophylaxis of GVHD and the side effects of this treatment. This is the first update on our review published in 2012 (<a href="./references#CD009159-bbs2-0086" title="TheurichS , FischmannH , Shimabukuro‐VornhagenA , ChemnitzJM , HoltickU , ScheidC , et al. Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD009159. [DOI: 10.1002/14651858.CD009159.pub2]">Theurich 2012</a>) and we could identify seven new studies. In the last decade more randomised controlled trials (RCTs) addressing the impact of ATG prophylaxis on GVHD have been published. We therefore decided to update our review and analyse the effects of ATG in this setting. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009159-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009159-sec-0019"></div> <p>To assess the administration of anti‐thymocyte globulins (ATG) used for the prevention of graft‐versus‐host disease (GVHD after allogeneic stem cell transplantation (SCT) with regard to overall survival, incidence and severity of acute and chronic GVHD), incidence of relapse, non‐relapse mortality, graft failure, adverse events, quality of life and incidence of infections. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009159-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009159-sec-0020"></div> <section id="CD009159-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009159-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled studies (RCTs). We excluded quasi‐randomised trials, for example in which the treatment allocation was conducted by alternation or by date of birth as this was classified as a poor study design leading to unreliable results. We included full‐text publications, abstract publications and unpublished data, if sufficient information was available. We planned to exclude cluster and or cross‐over randomised controlled studies in this review.  </p> </section> <section id="CD009159-sec-0023"> <h4 class="title">Types of participants</h4> <p>We considered adult participants of both sexes with an underlying haematological anomaly and an indication for allogeneic SCT. We excluded paediatric studies (patients younger than 18 years). Studies where patients younger than 18 were recruited were included only if the number of patients younger than 18 contributed to less than 20 % of the total number of patients in the trial. </p> </section> <section id="CD009159-sec-0024"> <h4 class="title">Types of interventions</h4> <section id="CD009159-sec-0025"> <h5 class="title">Experimental intervention</h5> <p> <ul id="CD009159-list-0001"> <li> <p>Addition of one type of anti‐thymocyte globulin (ATG) to the standard graft‐versus‐host disease (GVHD) prophylaxis and conditioning regimen. </p> <ul id="CD009159-list-0002"> <li> <p>We included any type of ATG, dosage and duration of administration.</p> </li> <li> <p>We excluded other co‐interventions, like other antibodies such as OKT3, alemtuzumab or rituximab with or without ATG as they are not biologically comparable to ATG alone. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD009159-sec-0026"> <h5 class="title">Control intervention</h5> <p> <ul id="CD009159-list-0003"> <li> <p>The same standard GVHD prophylaxis and conditioning regimen without ATG.</p> </li> </ul> </p> </section> </section> <section id="CD009159-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>We defined primary and secondary outcomes as follows.</p> <section id="CD009159-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>Overall survival of patients who received ATG compared with non‐ATG treated patients</p> </section> <section id="CD009159-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009159-list-0004"> <li> <p>Incidence and severity of acute GVHD</p> </li> <li> <p>Incidence and severity of chronic GVHD</p> </li> <li> <p>Incidence of relapse </p> </li> <li> <p>Non‐relapse mortality </p> </li> <li> <p>Graft failure</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> <p><b>Additional analyses (for this review update)</b> </p> <p> <ul id="CD009159-list-0005"> <li> <p>Quality of life</p> </li> <li> <p>Incidence of infections</p> </li> </ul> </p> <p>We revised the outcomes of interest in comparison to the previous version of this Cochrane Review, to reflect current standard reporting (see also <a href="#CD009159-sec-0118">Differences between protocol and review</a>). Non‐relapsed mortality and incidence of relapse was included, which were considered directly relevant to the addition of ATG as GVHD prophylaxis. Early 100‐day mortality after transplantation is not considered relevant nowadays due to improved supportive care post transplant, hence this outcome was not included. Our experience from the previous report highlighted a heterogenous reporting pattern for engraftment. Hence, we decided to analyse graft failure instead of engraftment.  </p> <p>Quality of life and the incidence of infection are outcomes of interest from the point of view of the clinician, as well as the patient. The addition of ATG is performed with the intention to reduce the risk of GVHD, which thereby probably increases the quality of life and reduces the incidence of infections. These two factors also influence the decision‐making process prior to implementing therapeutic strategies. Hence, these two new outcomes were analysed for this review. </p> <p>The outcomes were analysed a minimum of one year after the intervention. No maximum duration after the intervention was set for outcome analysis. </p> </section> </section> </section> <section id="CD009159-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009159-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We performed the search strategies in accordance with the suggestions in Chapter 6 of the <i>C</i>ochrane Handbook for Systematic Reviews of Interventions Version 5.1 (<a href="./references#CD009159-bbs2-0060" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: HigginsJPT , GreenS , editors(s). Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.">Lefebvre 2011</a>). We did not apply language restrictions in order to reduce potential language bias. <br/>CENTRAL, MEDLINE, trials registries and conference proceedings were searched for the previous version (<a href="./references#CD009159-bbs2-0086" title="TheurichS , FischmannH , Shimabukuro‐VornhagenA , ChemnitzJM , HoltickU , ScheidC , et al. Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD009159. [DOI: 10.1002/14651858.CD009159.pub2]">Theurich 2012</a>). </p> <p>In this update the search was conducted according to the strategies suggested by Higgins and colleagues (<a href="./references#CD009159-bbs2-0053" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:5928. [DOI: 10.1136/bmj.d5928] [PMID: 22008217]">Higgins 2011</a>).  A search was conducted on the 30th September 2021 and the last search was conducted on the 18 November 2022 (see <a href="./appendices#CD009159-sec-0110">Appendix 1</a>). </p> <p>For this update we searched the following databases</p> <p> <ul id="CD009159-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2022, Issue 11 </p> </li> </ul> </p> </section> <section id="CD009159-sec-0032"> <h4 class="title">Searching other resources</h4> <p>In the previous version of the article (<a href="./references#CD009159-bbs2-0086" title="TheurichS , FischmannH , Shimabukuro‐VornhagenA , ChemnitzJM , HoltickU , ScheidC , et al. Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD009159. [DOI: 10.1002/14651858.CD009159.pub2]">Theurich 2012</a>), we searched for abstracts from the conference proceedings of annual meetings of the following societies (electronically from 2000 to 2009 and manually from 2009 to 2010).  </p> <p>In this update the databases were searched, and search results were retrieved electronically from 2012 to November 2022. </p> <p> <ul id="CD009159-list-0007"> <li> <p>American Society of Haematology (ASH).</p> </li> <li> <p>American Society of Clinical Oncology (ASCO).</p> </li> <li> <p>European Group of Bone Marrow Transplantation (EBMT).</p> </li> <li> <p>American Society of Bone Marrow Transplantation (ASBMT).</p> </li> </ul> </p> <section id="CD009159-sec-0033"> <h5 class="title">Electronic search in databases of ongoing trials</h5> <p> <ul id="CD009159-list-0008"> <li> <p>MEDLINE, via OVID (on 18.11.2022)</p> </li> <li> <p>Embase, via OVID (on 18.11. 2022)</p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>) (searched and search results were retrieved on 18.11.2022) </p> </li> <li> <p>WHO ICTRP (<a href="https://trialsearch.who.int/AdvSearch.aspx" target="_blank">https://trialsearch.who.int/AdvSearch.aspx</a>) (searched and search results were retrieved on 18.11.2022 </p> </li> </ul> </p> <p>Embase registry was searched from 1974 and MEDLINE from February 2012.</p> </section> <section id="CD009159-sec-0034"> <h5 class="title">Handsearch of references</h5> <p> <ul id="CD009159-list-0009"> <li> <p>We checked references from all identified trials and not just all included studies, relevant review articles and current treatment guidelines for further literature. We checked all the references for all included studies. </p> </li> </ul> </p> <p>Our search methods and strategies were devised with the aim to reduce the likelihood to miss eligible studies. </p> </section> </section> </section> <section id="CD009159-sec-0035"> <h3 class="title" id="CD009159-sec-0035">Data collection and analysis</h3> <section id="CD009159-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GC and PF) independently selected studies from the titles and abstracts of studies identified from the above sources. At the first screening we excluded studies that were clearly ineligible. If this could not be done satisfactorily from the title or abstract, we obtained a full‐text version and discussed eligibility. The aim was to be overly inclusive rather than to risk losing relevant studies. We assessed the selected studies using an eligibility form to determine whether they met the inclusion criteria. We resolved any disagreement by discussion with a third review author (NS). If necessary, we sought further information from the authors where articles contained insufficient data to make a decision about eligibility. The eligibility form contained the following questions. </p> <p> <ul id="CD009159-list-0010"> <li> <p>Was the study described as randomised?</p> </li> <li> <p>Was the type and dose of ATG used for GVHD prophylaxis homogeneous, i.e. only one type (rabbit ATG Genzyme or ATG Fresenius) and dose of ATG in the treatment group? </p> </li> <li> <p>Is ATG the only intervention ie were agents other than ATG used in the intervention arm? </p> </li> </ul> </p> <p>To be eligible, studies had to meet all the criteria stated above. Duplicate reports were identified and discarded. Full‐text versions of all eligible studies for quality assessment and data collection were obtained. At every stage of searching and screening of the literature the overall number of studies identified, excluded and included with reasons were documented, see PRISMA flow diagram (<a href="./references#CD009159-bbs2-0063" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). Disagreements evolving at any stage were resolved by discussion and consensus was achieved by involving a third review author (NS). In the event of missing data, if considered relevant, the corresponding authors were sought to provide the relevant information. </p> </section> <section id="CD009159-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was conducted according to the guidelines proposed by Cochrane (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). We contacted authors of individual studies, if required, for additional information. For this review, two review authors (GC, PF) extracted data from the studies using a standardised data extraction form containing the following items. </p> <p> <ul id="CD009159-list-0011"> <li> <p>General information: author, title, source, publication date.</p> </li> <li> <p>Quality criteria such as risk of bias.</p> </li> <li> <p>Study characteristics: trial design, study aims, setting, trial dates, source of participants, inclusion and exclusion criteria, treatment allocation, comparability of groups, subgroup analysis, statistical methods, power calculations, treatment crossovers, compliance with assigned treatment, length of follow‐up, time point of randomisation (before or after transplantation). </p> </li> <li> <p>Participant characteristics: age; gender; ethnicity; number of participants recruited, allocated, evaluated; participants lost to follow‐up; additional diagnoses; type and intensity of previous chemotherapy, radiation and stem cell transplantation; general prognostic factors, e.g. Karnofsky index. </p> </li> <li> <p>Interventions: setting, dose, duration and type of ATG treatment, type and dose of chemotherapy and radiotherapy, supportive treatment. </p> </li> <li> <p>Outcomes: overall survival, acute and chronic GVHD, relapse, non‐relapse mortality, early mortality at day 100 after transplantation, progression‐free survival, quality of life, adverse events, engraftment. </p> </li> </ul> </p> <p>The review authors were not blinded to names of authors, institutions, journals or the outcomes of the trials. </p> </section> <section id="CD009159-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (GC and PF) assessed the eligible studies, obtained in the process of study selection as described above, for methodological quality and risk of bias. The quality assessment strongly depended upon information about the design, conduct and analysis of the trial. We determined if the criteria were fulfilled on a three‐point scale and used a summary description: yes (low risk of bias), no (high risk of bias), unclear. To assess quality and risk of bias, we used a questionnaire (validity assessment form) containing the following items as suggested in the Cochrane Handbook for Systematic Reviews of Interventions<i>,</i> version 6.2 updated February 2021 and the Cochrane risk of bias tool 1 (<a href="./references#CD009159-bbs2-0053" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:5928. [DOI: 10.1136/bmj.d5928] [PMID: 22008217]">Higgins 2011</a>). </p> <p> <ul id="CD009159-list-0012"> <li> <p>Sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding (participants, personnel, outcome assessors).</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged studies to be of unclear risk of bias when three or more domains of the Cochrane risk of bias tool were considered to be unclear and high risk of bias with one domain considered to be at high risk. PF and NS performed the GRADE ratings.  </p> </section> <section id="CD009159-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we calculated risk ratios (RRs) with 95 % confidence intervals (CIs) for each trial. We calculated continuous outcomes as standardised mean differences (SMDs). For time‐to‐event outcomes, we extracted the hazard ratio (HR) from published data according to Parmar and Tierney (<a href="./references#CD009159-bbs2-0070" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [PMID: 9921604]">Parmar 1998</a>; <a href="./references#CD009159-bbs2-0079" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007 June;8:16.">Tierney 2007</a>). </p> <p>To calculate absolute effects, we used the mean baseline risk from the control groups from the studies in the meta‐analysis as assumed risk. The corresponding risk for the intervention group (and its 95% CI) is based on the assumed risk in the control group and the relative effect of the intervention (and its 95% CI).<br/>The illustrative comparative risk on the per 1000 patients basis were calculated using <a href="./references#CD009159-bbs2-0049" title="GRADEpro Guideline Development Tool. McMaster University, 2020, developed by Evidence Prime, Inc., 2020. Available from gradepro.org..">GRADEpro GDT</a>. For time‐to event analyses we used the lowest and highest observed values in the included studies to calculate ranges for the illustrative comparative risks. </p> </section> <section id="CD009159-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>The aim of this review is to summarise studies that analyse data at the level of the individual. We collated multiple reports of one study so that the study, and not the report, is the unit of analysis.  </p> <section id="CD009159-sec-0041"> <h5 class="title">Studies with multiple treatment groups</h5> <p>As recommended in Cochrane Handbook for Systematic Reviews of Interventions, version 6.2 updated February 2021, for studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we planned to evaluate whether study arms were sufficiently homogeneous to be combined (Higgins 2021). If arms could not be pooled, we planned to compare each arm with the common comparator separately. For pair‐wise meta‐analysis, we planned to split the ‘shared’ group into two or more groups with smaller sample size, and include two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, we planned to divide both the number of events and the total number of participants, and for continuous outcomes, we planned to divide the total number of participants with unchanged means and standard deviations (SDs). </p> </section> </section> <section id="CD009159-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>There were many potential sources of missing data which needed to be taken into account: at study level, at outcome level, at summary data level, at individual level, and for study‐level characteristics (for example, for subgroup analysis) according to Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). If relevant data were missing,  we sought the information by personal communications with the corresponding authors. For this update no data were obtained by personal communications. </p> </section> <section id="CD009159-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>The heterogeneity of treatment effects between trials was assessed by using a Chi<sup>2</sup> test with the significance level at P &lt; 0.1. The I² statistic was used to quantify possible heterogeneity, and we used the following thresholds for heterogeneity according to the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). </p> <p> <ul id="CD009159-list-0013"> <li> <p>0 % to 40 %: are considered not important</p> </li> <li> <p>30 % to 60 %: represent moderate heterogeneity</p> </li> <li> <p>50 % to 90 %: represent substantial heterogeneity</p> </li> <li> <p>75 % to 100 %: represent considerable heterogeneity</p> </li> </ul> </p> <p>Potential causes of heterogeneity were explored by sensitivity and subgroup analyses using meta‐regression, but with the total number of studies less than 10, it was inappropriate to perform meta‐regression. </p> </section> <section id="CD009159-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>We only included peer‐reviewed and randomised controlled trials, (RCTs) which are less prone to publication bias than other article types. In meta‐analyses including 10 or more trials, potential publication bias can be assessed visually, f.e by funnel plot, and tested statistically, using a linear regression test (<a href="./references#CD009159-bbs2-0069" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Page 2021</a>). In this meta analysis, although 10 studies were included, we could obtain data from all 10 studies in only one end point, acute GvHD. Hence, we decided not to perform a funnel plot (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). Instead, we investigated possible publication bias by critically assessing study registries. <br/>A considerable amount, by comparison to the available body of evidence discussed in this article, of registered studies that did not result in a publication after completion would be considered an indicator of publication bias. We did not identify any such study which was not reported. Three ongoing studies were identified which we have highlighted, the second study is a parallel randomised control trial to the first study. In order to assess potential bias due to non‐reporting we searched for registry entries of the included studies. Full description of study details, including a priori definition of investigated outcomes, can be used to assess possible non‐reporting. </p> </section> <section id="CD009159-sec-0045"> <h4 class="title">Data synthesis</h4> <p>Analyses were performed according to the recommendations of Cochrane Handbook for Systematic Reviews of Interventions <i>(</i><a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). Aggregated data were used for analysis. For statistical analysis, we entered the data into the Cochrane statistical programme, version 2.5 (<a href="./references#CD009159-bbs2-0074" title="Review Manager Web (RevMan Web). Version Version: 2.5.0. The Cochrane Collaboration, 2021, 06 Apr. available at revman.cochrane.org.">RevMan Web 2021</a>). One review author entered the data and a second review author checked for accuracy. The meta‐analyses was performed using a fixed‐effect model (for example, the generic inverse variance method for survival data outcomes and Mantel‐Haenszel method for dichotomous data outcomes). <br/>We based the decision for the fixed‐effect model on the assumption of the intervention effects being identical between the studies as they are homogenous from a clinical perspective. As recommended in the Cochrane Handbook we have supplemented our decision with an investigation of heterogeneity. </p> <p>We did not restrict either studies with high risk of bias or studies with unclear bias from the analyses, but planned to investigate the influence of studies with high risk of bias in a sensitivity analysis. </p> <p>The <a href="./references#CD009159-bbs2-0049" title="GRADEpro Guideline Development Tool. McMaster University, 2020, developed by Evidence Prime, Inc., 2020. Available from gradepro.org..">GRADEpro GDT</a> was used to create summary of finding tables as suggested in the Cochrane Handbook for Systematic Reviews of Intervention (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). </p> </section> <section id="CD009159-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Because of clinical relevance, we performed subgroup analyses for the following characteristics for every outcome in which respective data were available, irrespective of observed statistical heterogeneity.   </p> <p>We evaluated the following subgroups.</p> <p> <ul id="CD009159-list-0014"> <li> <p>Type of ATG (ATG‐Fresenius vs thymoglobulin)</p> </li> <li> <p>Dosage of ATG‐F (≤ 30 mg vs &gt;30 mg)</p> </li> <li> <p>Dosage of thymoglobulin (≤ 4.5mg vs &gt; 4.5 mg)</p> </li> <li> <p>Donor type (sibling vs matched unrelated donors (MUDs)</p> </li> </ul> </p> <p>We used the tests for interaction to test for differences between subgroup results (P &lt;= 0.05). </p> </section> <section id="CD009159-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>In the presence of high‐risk studies, we planned on performing a sensitivity analysis. Neither studies with high risk of bias nor studies with unclear risk of bias were restricted from the analyses. Downgrading of data was decided to be done only if more than three studies had an unclear risk of studies. As only three studies had unclear risk of bias we did not perform a sensitivity analysis. </p> </section> <section id="CD009159-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD009159-sec-0049"> <h5 class="title">Assessment of the certainty of the evidence</h5> <p>Two review authors (PF and NS) used the GRADE approach to assess the certainty of the evidence. The GRADE approach uses five considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty in the body of evidence for each prioritised outcome, and to draw conclusions about the certainty of evidence within the text of the review. We followed the current GRADE guidance for these assessments in its entirety, as recommended in chapter 14, Cochrane Handbook Version (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). </p> <p>The overall risk of bias (RoB) judgement, derived from the individual RoB, was used to inform decision‐making on grading for risk of bias. For time‐to‐event outcomes, absolute effects at specific time points as recommended in the GRADE guidance 27 were used (<a href="./references#CD009159-bbs2-0077" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31.">Skoetz 2020</a>). The findings and certainty of the evidence were phrased as suggested in the informative statement guidance (<a href="./references#CD009159-bbs2-0075" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> <section id="CD009159-sec-0050"> <h5 class="title">Summary of findings table</h5> <p>By using GRADEpro GDT software (GRADEpro GDT) we created a summary of findings table, as suggested in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD009159-bbs2-0054" title="Higgins JPT ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA  (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Vol. Available from www.training.cochrane.org/handbook. Cochrane, 2022.">Higgins 2022</a>). </p> <p> <ul id="CD009159-list-0015"> <li> <p>Overall survival</p> </li> <li> <p>Acute GvHD II‐IV</p> </li> <li> <p>Overall chronic GvHD</p> </li> <li> <p>Incidence of relapse</p> </li> <li> <p>Non‐relapse mortality</p> </li> <li> <p>Graft failure</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009159-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009159-sec-0051"></div> <section id="CD009159-sec-0052"> <h3 class="title">Description of studies</h3> <p>Study details are summarised in tables at the following sections: <a href="./references#CD009159-sec-0125" title="">Characteristics of included studies</a>, <a href="./references#CD009159-sec-0126" title="">Characteristics of excluded studies</a> and <a href="./references#CD009159-sec-0127" title="">Characteristics of ongoing studies</a> </p> <section id="CD009159-sec-0053"> <h4 class="title">Results of the search</h4> <p>For this update we identified 1858 references. 590 duplicates were removed.1209 were excluded after title abstract screening. We obtained 59 full‐text articles for further assessment. Seven studies (31 references) were included, three studies were ongoing and 19 studies (25 references) were excluded. We included three studies from the first version of this Cochrane Review and excluded three studies, as they included more than 20 % patients below 18 years of age. The PRISMA flow diagram describes the selection process (<a href="#CD009159-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009159-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD009159-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>No experts in the field were contacted in order to retrieve other trials for this update. We contacted the authors of two published RCT (<a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) in order to obtain more information about their data, but did not receive any reply. Only published data have been used for the data in this review. </p> </section> <section id="CD009159-sec-0054"> <h4 class="title">Included studies</h4> <section id="CD009159-sec-0055"> <h5 class="title">Included studies</h5> <p>For this update seven further randomised controlled studies (RCTs) were included (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). The previous version included six studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0018" title="ChamplinRE , PerezWS , PasswegJR , KleinJP , CamittaBM , GluckmanE , et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood2007;109(10):4582-5. ">Champlin 2007</a>; <a href="./references#CD009159-bbs2-0020" title="DoneyKC , WeidenPL , StorbR , ThomasED . Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation1981;31(2):141-3. ">Doney 1981</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0029" title="WeidenPL , DoneyK , StorbR , ThomasED . Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation1979;27(4):227-30. WeidenPL , DoneyK , StorbR , ThomasED . Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplantation Proceedings1978;10(1):213-6. ">Weiden 1979</a>). For the purposes of this review three studies (<a href="./references#CD009159-bbs2-0018" title="ChamplinRE , PerezWS , PasswegJR , KleinJP , CamittaBM , GluckmanE , et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood2007;109(10):4582-5. ">Champlin 2007</a>; <a href="./references#CD009159-bbs2-0020" title="DoneyKC , WeidenPL , StorbR , ThomasED . Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation1981;31(2):141-3. ">Doney 1981</a>; <a href="./references#CD009159-bbs2-0029" title="WeidenPL , DoneyK , StorbR , ThomasED . Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation1979;27(4):227-30. WeidenPL , DoneyK , StorbR , ThomasED . Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplantation Proceedings1978;10(1):213-6. ">Weiden 1979</a>) were excluded as more than 20 % of the patients included were below 18 years of age. We included 10 studies for the purposes of this review. Nine studies were published in English and one study was published in Chinese (<a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). Outcome data of 1413 patients were evaluated. The recruitment periods ranged from 1976 until 2019, with a maximum median follow‐up time of three years (<a href="#CD009159-tbl-0003">Table 2</a>). </p> <div class="table" id="CD009159-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study design /</b> </p> <p><b>Study</b> </p> <p><b>dates</b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sample size (ATG/</b> </p> <p><b>Control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> <p><b>ATG/ Control</b> </p> <p><b>Median (range)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sex<br/>ATG(M/F):</b> </p> <p><b>Control (M/F)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Donor; <br/>HLA match;</b> </p> <p><b>Stem cell source; Conditioning;</b> </p> <p><b>Immuno‐suppression</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention ATG; Dose; Days of administration</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported Outcomes</b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median duration of follow‐up<br/>ATG/ control</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Declaration of interest /</b> </p> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec. 1995 ‐ Dec. 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54(29/25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28(18‐48)/ <br/>29 (13‐51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Full match (6/6)</p> <p>BM;</p> <p>Cy/ TBI;</p> <p>CsA/Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin; 7,5mg/kg; ‐4, ‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Acute GVHD </p> <p><b>Secondary:</b> Overall survival, chronic GVHD, non‐relapse mortality, incidence of relapse, engraftment, event‐free survival. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34 years/ 2.85 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided /</p> <p>Government and Private sector funding (Sangstat)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec. 1995 ‐ Dec. 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 (27/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (14‐52)/</p> <p>28 (14‐46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Full match (6/6);</p> <p>BM; <br/>Cy/ TBI; </p> <p>CsA/Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>15mg/kg;</p> <p>‐5, ‐4,‐3,‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Acute GVHD </p> <p><b>Secondary:</b>Overall survival, chronic GVHD, non‐relapse mortality, incidence of relapse, engraftment, event‐free survival. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 years/</p> <p>1.47 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided /</p> <p>Government and Private sector funding (Sangstat)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Nov.2013 ‐ April 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263(132/131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (40‐61)/<br/>46 (40‐58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(76/56): (75/56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB;</p> <p>Full match;</p> <p>ATG</p> <p>PB 76: BM 6: PB+BM50, Control</p> <p>PB 77: BM 3:</p> <p>PB+BM 51;</p> <p>CyTBI, BuCY, FluBU;</p> <p>CsA+ Mtx +MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>4.5mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> grade 2‐4 aGVHD on day 100. </p> <p><b>Secondary:</b> Engraftment, chronic GvHD 2 years, Immune‐suppressant free at 2 years and 3 years ‐non‐relapse mortality, GvHD related Non relapse mortality, cumulative incidence of relapse, overall survival, leukaemia free survival as well as graft versus host disease relapse free survival, Infections </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,163 days (range 182‐2027 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /</p> <p>Governmental funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>April 2017 ‐Jan. 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120(60/60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.5(18‐64)/</p> <p>47.5(20‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(23/37):(36/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB; Fully matched(4/4)ATG (35): Control (39), Major mismatch ATG (12): control (8), Minor mismatch ATG (6): Control (7), major and minor mismatch ATG (7), Control (6); </p> <p>PB; BuCy or CyTBI or FluBU or FluBuTBI; CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin 2.5mg/kg; 1.25mg/kg/day on days ‐3 and ‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> GVHD at 2 years </p> <p><b>Secondary:</b> Engraftment; Immune reconstitution; Cumulative incidences of acute GVHD; Infectious complications relapse (CIR); non relapse mortality and disease free survival; overall survival; a composite end point of chronic GVHD free and relapse free survival; Recipient reported outcomes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /<br/>Not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Aug. 2015 ‐ Dec. 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72(42/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6(38‐62)/</p> <p>45.6(36‐63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(24/18): (18/12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB; Fully matched (6/6) ATG (25): control (17). Major mismatch ATG(7):control (8)Minor mismatch ATG (8): control (5), Bidirectional mismatch ATG (2): control(0) </p> <p>PB;</p> <p>BuCy or CyTBI or FluBu; CsA+ Mtx+MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin; 5mg/kg; 1,5mg/kg on day‐5 and 3.5mg/kg on day ‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Incidence of chronic GVHD at 2 years </p> <p><b>Secondary:</b> Non‐relapsed mortality; relapse GVHD‐free; relapse free survival; incidence of a GvHD; engraftment, DFS; OS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>874 days or 29 months</p> <p>(962 days for patients alive, 391 days for patients died)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /</p> <p>Governmental funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>May 2003 ‐ Feb. 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201(103/98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (18‐60)/</p> <p>39 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(58/45): (58/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>35 HLA ‐ C mismatched</p> <p>All others fully matched (8/8)</p> <p>ATG</p> <p>PB:BM 82:21, control</p> <p>PB:BM 82:16; <br/>CyTBI or BuCy; </p> <p>CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F; 60mg/kg; ‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> severe aGvHD grade III‐IV or death </p> <p><b>Secondary:</b> Overall survival, acute GVHD, chronic GVHD, non‐relapse mortality, adverse effects, disease‐free survival, incidence of relapse, engraftment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 years/1.81 years Update 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Lecture fees from Fresenius Biotech GmbH) /</p> <p>Private sector funding (Fresenius Biotech GmbH)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec.2006 ‐ Feb. 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155(83/72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18‐64)/</p> <p>43.5 (21 ‐ 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(53/30): (40/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB;</p> <p>Full match;</p> <p>PB; BuCy +/‐ Etoposide;</p> <p>CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>30mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> 2‐year cumulative<br/>incidence of chronic GVHD </p> <p><b>Secondary:</b> Cumulative incidence of chronic GVHD at 2 years, incidences of engraftment, acute GVHD, nonrelapse‐related death, relapse‐free and overall survival at 2 years, and a composite end point of chronic GVHD–free and relapse‐free survival at 2 years, Infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Lecture fees (Neovii Biotech) /</p> <p>Medical associations and Private sector funding (Neovii Biotech)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Oct. 2011 ‐ Oct. 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (126/128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (18‐64)/</p> <p>49 (19‐65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(60/66): (79/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Allele‐level matched at HLA‐A, ‐B, ‐C, and ‐DRB1;</p> <p>ATG</p> <p>PB:BM:NK</p> <p>95: 22:9, Control</p> <p>PB:BM:NK</p> <p>101:27:0;</p> <p>CyTBI, BuCy, FluBU;</p> <p>Tac+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>20mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Moderate‐severe cGVHD‐free survival </p> <p><b>Secondary:</b> overall survival (OS), progression‐free survival (PFS), moderate‐severe cGVHD‐free and relapse‐free survival (cGRFS), cumulative incidence of relapse and nonrelapse mortality (NRM), acute GVHD, and engraftment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Consulting fees and honoraria /</p> <p>Individual funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>June 2010 ‐ July 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196 (99/97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐57)/</p> <p>49 (40‐56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(63/36): (65/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>ATG: 83 Full match, 16 one allele mismatch</p> <p>Control:</p> <p>79 Full match, 18 one allele mismatch;</p> <p>ATG</p> <p>PB:BM 88:11, control PB:BM 85:12;</p> <p>Myelo and non‐myeloablativ;</p> <p>CsA orTac and</p> <p>Mtx or MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>4,5mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Freedom from systemic immunosuppressive drugs without resumption up to 12 months after transplantation<br/><b>Secondary:</b> time to neutrophil and platelet engraftment (analysed only for patients undergoing myeloablative conditioning); the incidence of AGVHD; the incidence of and time to CGVHD; times to non‐relapse mortality, all‐cause mortality, and relapse of haematological malignancy; event‐free survival; graft rejection or failure (yes vs no); incidence of serious infection and cytomegalovirus reactivation; doses of immunosuppressive therapy at 12 months; and recipient‐reported outcomes (quality of life) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Membership on advisory board (Sanofi) /</p> <p>Government and Private sector funding (Sanofi)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Date not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (19/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4‐42)/</p> <p>(12‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>ATG 14 fully matched 5 mismatched/ Control 18 fully matched 6 mismatched;</p> <p>NR; FluBuCy;</p> <p>CsA+ MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>37.5mg/kg;</p> <p>‐5, ‐4,‐3,‐2,‐1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute GVHD, chronic GVHD, quality of life.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 days (150‐490)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported /</p> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SIB: Sibling, MUD: Matched unrelated donor, PB: Peripheral blood, BM: Bone marrow, NK: Not known, BuCy: Busulfan Cyclophosphamide, CyTBI: Cyclophosphamide Total body irradiation, FluBu: Fludarabine Busulfan, CsA: Cyclosporin A, Tac: Tacrolimus, MMF: Mycophenolate Mofetil, Mtx: Methotrexate </p> </div> </div> </section> <section id="CD009159-sec-0056"> <h5 class="title">Anti‐thymocyte globulins (ATG) preparations</h5> <p>Four ATG preparations were compared to standard GVHD prophylaxis in the trials. Four studies used rabbit ATG Fresenius (ATG‐F) (<a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>), and six studies analysed rabbit ATG Genzyme (Thymoglobulin) (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). All the studies in this update used rabbit ATG. Details of sources and dosages of the different ATG types are summarised in <a href="#CD009159-tbl-0004">Table 3</a>. </p> <div class="table" id="CD009159-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ATG used in intervention arm</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of ATG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dosage</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (Sangstat, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.75mg/kg on days ‐4, ‐3 (total dose 7.5 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (Sangstat, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.75mg/kg on days ‐5, ‐4, ‐3, ‐2 (total dose 15mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐10mg/kg on days ‐4,‐3,‐2,‐1 and 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F (Fresenius, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20mg/kg on days ‐3, ‐2, ‐1 before transplantation (total dose 60 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG [formerly termed ATG‐Fresenius] (Fresenius, Neovii Biotech)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10mg/kg/day on days ‐3,‐2, ‐1,</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐Sanofi, (rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG [formerly termed ATG‐Fresenius] (Neovii Biotech)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg/day on days ‐3,‐2, ‐1,</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐Sanofi, (rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (rabbit ATG, Sanofi, Paris, France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5mg/kg (1,5mg/kg day ‐5 and 3.5mg/kg day ‐4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐ Sanofi, Cambridge MA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5mg/kg: 1.25mg/kg/day on days ‐3 and ‐2</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>[Day 0 is day of transplant]</p> </div> </div> </section> <section id="CD009159-sec-0057"> <h5 class="title">Standard Graft‐versus‐host disease (GVHD) prophylaxis</h5> <p>For GVHD prophylaxis, methotrexate was used in all studies whereas cyclosporin was used in nine trials (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). Tacrolimus was used instead of cyclosporin by <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>, whereas <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> used cyclosporin or tacrolimus. Mycophenolate mofetil (MMF) was used as a third immune‐suppressant in the first one month post‐transplant in three trials (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). Details regarding GVHD prophylaxis are summarised in <a href="#CD009159-tbl-0005">Table 4</a>. </p> <div class="table" id="CD009159-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Standard GVHD Prophylaxis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cyclosporine (CsA)/ Tacrolimus (Tac)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methotrexate</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mycophenolate Mofetil (MMF)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA 2mg/kg from day ‐1 to +20, then 6 to 10 mg/kg per day for at least 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m² on day +1,</p> <p>10 mg/m² on days +3,+6 and +11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with a plasma concentration of 150‐300ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1, </p> <p>10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA Target concentration 200 ng/mL, tapered after day 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m² day 1,</p> <p>10 mg/m² days +3, +6, +11.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1 and </p> <p>10 mg/m<sup>2</sup> on days +3, +6, and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA or Tac administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Administered, but dosage not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tac (with a target serum trough level of 5 to 15 ng/mL) and IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m2 on day +1, 10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 mg/kg CsA continuous intravenous drip, started on day 21, changed to orally when GI function recovered with a dose of 5 mg/kg administered as 2 divided doses, and CsA trough concentration maintained at 200‐ 300 ng/mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1 and 10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 g MMF twice a day, starting on day +21 and continuing to day +30 for 1 month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with concentration 150‐ 250 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1, </p> <p>10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5g twice daily from days ‐10 to +14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with concentration 150‐300ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10mg/m<sup>2</sup> on days +1, +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Day 0 is day of transplant.</p> </div> </div> </section> <section id="CD009159-sec-0058"> <h5 class="title">Conditioning regimens</h5> <p>In nine out of 10 studies patients were treated with myeloablative conditioning regimens including total body irradiation. Reduced intensity conditioning (RIC) regimen was used only in the study by <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>. <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> used a non‐myeloablative conditioning regimen. <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> did not use a standard myeloablative conditioning regimen. A comparison of conditioning regimens is presented in <a href="#CD009159-tbl-0006">Table 5</a>. </p> <div class="table" id="CD009159-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Conditioning therapy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conditioning regimen</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TBI [centre specific: 12 Gy (2 Gy twice a day for 3 days), 9 Gy (3.3 Gy for 3 days), 13.2 Gy (120 cGy for 11 days) and (10 Gy single dose)]plus Cy (dosage not reported), N = 54 (100%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fludarabine 25 mg / m<sup>2</sup> (day‐8 to ‐4), Bu 3 mg/kg (day ‐8 to ‐5) and cyclophosphamide 60 mg / kg (day‐4 to‐3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TBI (8‐12 Gy) plus Cy (2 doses of 60 mg / kg): N = 102 (50.5 %), Busulfan (14 to 16 mg/kg orally) plus Cyclophosphamide (2x60 mg / kg): N = 52 (25.7 %), other myeloablative regimens: N = 47 (23.3 %) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cy (120 mg/kg) and TBI (12 Gy) or Bu (16 mg/kg orally or 12.8 mg/kg IV), with or without etoposide (30 to 60 mg/kg) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myeloablative or non‐myeloablative and reduced‐intensity conditioning regimens.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CyTBI:Cy (120 mg/kg total intravenously (IV)) and fractionated TBI (12 Gy); BuCy: Bu 16 mg/kg orally or 12.8 mg/kg IV and Cy 120 mg/kg IV; BuFlu, Busulfan 16 mg/kg orally or 12.8 mg/kg IV and fludarabine 120 mg/m<sup>2</sup> IV. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BuCy, TBI and FluCy or FluBu</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BuCY, CyTBI and FluBU</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bu (12.8 mg / kg) Cy (120 mg / kg), Cy (120 mg/kg) TBI (1320 cGy of fractionated TBI) or Flu (150 mg/ m<sup>2</sup>) Bu (6.4 mg/ kg) or Flu (150 mg/m<sup>2</sup>)Bu (6.4 mg / kg) TBI (400 cGy of fractionated TBI) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Cy: Cyclophosphamide, Bu: Busulfan, Flu: Fludarabine, TBI: Total body irradiation, IV: intravenously </p> </div> </div> </section> <section id="CD009159-sec-0059"> <h5 class="title">Patient characteristics</h5> <section id="CD009159-sec-0060"> <h6 class="title">Age</h6> <p>Median patient age of all included studies ranged from 26 to 49 years and absolute age from 4 to 65 years. The study by <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>, as well as the seven studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>, <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) added in this update stated age above 18 years as an inclusion criterion. In the three other studies patients younger than 18 years were evaluated but accounted for less than 20 % of the total (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). Details regarding patient age are summarised in <a href="#CD009159-tbl-0007">Table 6</a>. </p> <div class="table" id="CD009159-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Patient characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median age</b> </p> <p><b>(range) ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median age</b> </p> <p><b>(range) control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Male(%) ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Male(%) Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Underlying disease ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Underlying disease Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Early‐stage disease</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Advanced‐stage disease</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (18‐48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (13‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:62%</p> <p>Control:60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:38%</p> <p>Control:40%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (14‐52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (14‐46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:22%</p> <p>Control:36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:78%</p> <p>Control:64%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (4‐42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (12‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:7</p> <p>AML:6</p> <p>ALL:3</p> <p>AA: 2</p> <p>Thalassaemia:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:8</p> <p>AML:10</p> <p>ALL:5</p> <p>NHL:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: N = 37<br/>AML: N = 55<br/>CML: N = 6<br/>MDS: N = 5<br/>OMF: N = 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: N = 33<br/>AML: N = 46<br/>CML: 11<br/>MDS: N = 5<br/>OMF: N = 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:62 %</p> <p>Control:44 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:38 %</p> <p>Control:56 %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18 ‐ 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (21‐ 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: 55</p> <p>AML 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:55</p> <p>ALL:17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML: 7 (7 %)</p> <p>AML: 39 (39 %)</p> <p>ALL:13 (13 %)</p> <p>MDS:11 (11 %)</p> <p>CLL:8 (8 %)</p> <p>NHL:14 (14 %)</p> <p>Other:7 (7 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:5 (5 %)</p> <p>AML:39 (40 %)</p> <p>ALL:16 (17 %)</p> <p>MDS:12 (12 %)</p> <p>CLL:8 (8 %)</p> <p>NHL:13 (13 %)</p> <p>Other:4 (4 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:57 (58 %)</p> <p>Control:59 (61 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:34 (34 %)</p> <p>Control:N = 34 (35 %)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (18‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (19‐65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:24 (19 %)</p> <p>AML:83 (66 %)</p> <p>MDS:19 (15 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:34 (26.6 %)</p> <p>AML:80 (62.5 %)</p> <p>MDS:14 (10.9 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (40‐61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (40‐58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:88 (66.7 %)</p> <p>ALL:18 (13.6 %)</p> <p>CML:2 (1.5 %)</p> <p>MDS:24(18.2 %)</p> <p>NHL:0 (0 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:88 (67.2 %)</p> <p>ALL:16 (12.2 %)</p> <p>CML:1 (0.8 %)</p> <p>MDS:23 (17.6 %)</p> <p>NHL:3 (2.3 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6 (38‐62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.6 (36‐63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:21</p> <p>ALL:12</p> <p>MDS:9</p> <p>NHL:0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:14</p> <p>ALL:5</p> <p>MDS:9</p> <p>NHL:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (20‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (18‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:33 (55 %)</p> <p>ALL:27(45 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:33 (55 %)</p> <p>ALL:27(45 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk ATG (8): Control (9)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* A follow‐up publication (<a href="./references#CD009159-bbs2-0038" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5.">Bacigalupo 2006</a>) reported pooled underlying disease of patients surviving day 100 of both studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>): Intervention group: Acute Leukaemia: N = 11, CML: N = 27, MDS: N = 0; Control group: Acute Leukaemia: N = 11, CML: N = 25, MDS: N = 1. </p> <p>Abbreviations: SAA: Severe aplastic anaemia; AML: Acute myeloid leukaemia; ALL: Acute lymphoid leukaemia; CML: Chronic myeloid leukaemia; LLL: Leukaemic lymphoblastic lymphoma; MDS Myelodysplastic syndrome; OMF: Osteomyelofibrosis; NHL Non‐Hodgkin Lymphom; N‐not reported </p> </div> </div> </section> <section id="CD009159-sec-0061"> <h6 class="title">Underlying disease</h6> <p>Underlying diseases included acute and chronic leukaemia, myelodysplastic syndrome, non‐Hodgkin lymphoma and osteomyelofibrosis (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). Bacigalupo (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>) reported data on two sequential trials. In the first trial (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>) there were slightly more patients with early‐stage disease. In contrast, in the following trial (<a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>) patients with advanced‐stage disease were a large proportion of the patients. The patients analysed in the study of <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> were balanced with regard to the stage of the disease, with a slight majority of patients with early‐stage disease in the intervention group. The seven studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) added in this update did not report disease stage. Disease characteristics are presented in <a href="#CD009159-tbl-0007">Table 6</a>. </p> </section> </section> <section id="CD009159-sec-0062"> <h5 class="title">Graft characteristics</h5> <p>Of all 1413 patients, 227 patients (16 %) received a bone marrow (BM) transplant, whereas 1033 patients (73 %) received peripheral blood stem cells (PBSC). In the study by <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> 101 (7 %) patients received both BM and PBSC. No data were available for 52 (4 %) patients. See <a href="#CD009159-tbl-0003">Table 2</a> for details. </p> <p>Grafts were obtained from matched unrelated donors (MUDs) (six out of six alleles); serology (HLA‐A, HLA‐B) and DNA‐based (HLA‐DRB1) in the studies of Bacigalupo (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>). In the study <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>, 196 patients (98%) received grafts from MUDs (eight out of eight DNA based alleles; HLA‐A, HLA‐B, HLA‐DQB1, HLA‐DRB1). In thirty‐five (17 %) patients the donor had a single allele mismatch (HLA‐C), i.e. an HLA‐C mismatch. <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> and <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> recruited matched HLA identical sibling donors, but did not specify the HLA loci. <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> recruited MUDs which were matched at HLA loci A, B, C and DRB 1. <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> recruited 162 (83 %) MUDs and 34 (17 %) with one allele mismatch in HLA loci A, B, C or DRB 1. <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> and <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> recruited only sibling donors. <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> matched 4 out of 4 alleles and <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> 6 out 6 alleles. The patients were fully matched or with a major or minor allele mismatch. </p> <p>Data about the tested HLA alleles used in the matching analyses were only reported in three of the included studies: Participants in the study <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> received grafts matching eight out of eight alleles (HLA‐A, HLA‐B, HLA‐DRB1, HLA‐DQB1, DNA‐based) whereas in the Bacigalupo studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>), participants received graft matching six out of six alleles [HLA‐A, HLA‐B (serology‐based); HLA‐DRB1 (DNA‐based)]. </p> </section> </section> <section id="CD009159-sec-0063"> <h4 class="title">Ongoing studies</h4> <p>We identified three ongoing studies (<a href="./references#CD009159-bbs2-0030" title="JPRN-jRCTs031180435. A randomized trial of ATG in HLA 1-locus mismatched unrelated bone marrow transplantation. https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs0311804352019. ">JPRN‐jRCTs031180435</a>; <a href="./references#CD009159-bbs2-0031" title="JPRN-UMIN000028008. A randomized trial comparing conventional GVHD prophylaxis vs. anti-thymocyte globulin-combined GVHD prophylaxis in HLA 1-locus mismatched unrelated bone marrow transplantation. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000308402017. ">JPRN‐UMIN000028008</a>; <a href="./references#CD009159-bbs2-0032" title="NCT04203108. ATG in HLA-matched sibling HSCT as GVHD prophylaxis. https://clinicaltrials.gov/show/NCT042031082019. ">NCT04203108</a>). The details of the ongoing studies are described in <a href="#CD009159-tbl-0008">Table 7</a>. The second study (<a href="./references#CD009159-bbs2-0031" title="JPRN-UMIN000028008. A randomized trial comparing conventional GVHD prophylaxis vs. anti-thymocyte globulin-combined GVHD prophylaxis in HLA 1-locus mismatched unrelated bone marrow transplantation. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000308402017. ">JPRN‐UMIN000028008</a>) is a parallel randomised controlled trial (RCT) to the first study (<a href="./references#CD009159-bbs2-0030" title="JPRN-jRCTs031180435. A randomized trial of ATG in HLA 1-locus mismatched unrelated bone marrow transplantation. https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs0311804352019. ">JPRN‐jRCTs031180435</a>). </p> <div class="table" id="CD009159-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No: of patients</b> </p> <p><b>Total (ATG/</b> </p> <p><b>Control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> <p><b>ATG/ Control</b> </p> <p><b>Median (range)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex</b> <br/><b>ATG(M/F):</b> </p> <p><b>Control (M/F)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Donor; HLA match</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stem cell source</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conditioning;</b> </p> <p><b>Immunosuppression</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ATG; Dose; Days of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0030" title="JPRN-jRCTs031180435. A randomized trial of ATG in HLA 1-locus mismatched unrelated bone marrow transplantation. https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs0311804352019. ">JPRN‐jRCTs031180435</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 in total, estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age ≥ 16 and ≤ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Men and Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Related or Unrelated; Matched and mismatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 ‐ 0.03 mg/kg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Death, Relapse, </p> <p>Grades III‐IV acute GVHD,</p> <p>Severe chronic GVHD or mild chronic GVHD requiring systemic steroid treatment)</p> <p><b>Secondary:</b> Cumulative incidence of neutrophil engraftment, Cumulative incidence of platelet engraftment, Cumulative incidence of acute GVHD and severity, Cumulative incidence of chronic GVHD and severity, Cumulative incidence of relapse, Cumulative incidence of non‐relapse mortality, </p> <p>Probability of disease‐free survival, Probability of overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0031" title="JPRN-UMIN000028008. A randomized trial comparing conventional GVHD prophylaxis vs. anti-thymocyte globulin-combined GVHD prophylaxis in HLA 1-locus mismatched unrelated bone marrow transplantation. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000308402017. ">JPRN‐UMIN000028008</a> </p> <p>Parallel randomised controlled trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 in total, estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age ≥ 16 and ≤ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Men and Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unrelated; HLA 1‐locus mismatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 ‐ 0.03 mg/kg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Success rate at 1 year after transplantation; Death; Relapse;<br/>Grades III‐IV acute GVHD; Severe chronic GVHD or mild chronic GVHD requiring systemic steroid treatment) </p> <p><b>Secondary:</b> Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0032" title="NCT04203108. ATG in HLA-matched sibling HSCT as GVHD prophylaxis. https://clinicaltrials.gov/show/NCT042031082019. ">NCT04203108</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimated n = 266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age of 18‐65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sibling; Matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> </p> <p>Incidence of cGVHD 2 years</p> <p><b>Secondary:</b> Overall survival 2 years; </p> <p>Disease‐free survival; 2 years,</p> <p>Incidence of aGVHD 100 days, 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Governmental funding</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009159-sec-0064"> <h4 class="title">Excluded studies</h4> <p>19 studies were excluded for the following reasons.</p> <p> <ul id="CD009159-list-0016"> <li> <p>Five studies were excluded because of non‐randomised design (<a href="./references#CD009159-bbs2-0013" title="AttaEH , deSousaAM , SchirmerMR , BouzasLF , NucciM , AbdelhayE . Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biology of Blood &amp; Marrow Transplantation2012;18(12):1876-82. ">Atta 2012</a>; <a href="./references#CD009159-bbs2-0014" title="BacigalupoA , LamparelliT , GualandiF , BreganteS , RaiolaAM , Di Grazia C et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biology of Blood and Marrow Transplantation2002;8(12):656-61. ">Bacigalupo 2002</a>; <a href="./references#CD009159-bbs2-0022" title="MediavillaC , VigourouxS , TabriziR , PigneuxA , DuclosC , MohrC , et al. Transient grades 3 to 4 acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation. Biology of Blood &amp; Marrow Transplantation2015;21(4):661-5. ">Mediavilla 2015</a>; <a href="./references#CD009159-bbs2-0023" title="MensenA , NaIK , HaferR , MeerbachA , SchlechtM , PietschmannML , et al. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. Journal of Cancer Research &amp; Clinical Oncology2014;140(11):1971-80. ">Mensen 2014</a>; <a href="./references#CD009159-bbs2-0025" title="PidalaJ , TomblynM , NishihoriT , AyalaE , FieldT , FernandezH , et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biology of Blood &amp; Marrow Transplantation2011;17(8):1237-44. ">Pidala 2011</a>). </p> </li> <li> <p>Alemtuzumab, Rituximab, Fludarabine or post transplantation cyclophosphamide with ATG as intervention in five studies (<a href="./references#CD009159-bbs2-0011" title="AlgarottiA , MicoC , CorradiniP , FaldaM , AlessandrinoEP , FaninR , et al. In vivo T cell depletion with antithymocyte globulin or alemtuzumab for unrelated donor stem cell transplantation with reduced intensity conditioning: Results of a multicenter randomized phase II clinical trial (the global study) from the gruppo italiano trapianto di midollo osseo (gitmo). In: Haematologica. Vol. 98. 2013:17. AlgarottiA , MicoC , CorradiniP , FaldaM , AlessandrinoEP , FaninR , et al. In vivo T-cell depletion with antithymocyte globulin or alemtuzumab for unrelated donor stem cell transplantation with reduced intensity conditioning: Results of a multicentre randomized phase II clinical trial (the Global study) from the GITMO. In: Bone Marrow Transplantation. Vol. 48. 2013:S60-S61. ">Algarotti 2013</a>; <a href="./references#CD009159-bbs2-0012" title="AlgeriM , GalimbertiS , BernardoME , RovelliA , ZeccaM , NasaGL , et al. Results of a multicentre, randomized, controlled open-label study on the use of anti-t-lymphocyte globulin (ATLG) and rituximab for immunomodulation of graft-versus-host disease (GvHD) and graft failure (GF) in patients with non-malignant disorders. In: Blood. Vol. 134. 2019. ">Algeri 2019</a>; <a href="./references#CD009159-bbs2-0016" title="BaronF , ZacheeP , MaertensJ , KerreT , OryA , SeidelL , et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology &amp; Oncology2015;8:4. HannonM , BeguinY , EhxG , ServaisS , SeidelL , GrauxC , et al. Immune recovery after allogeneic hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG conditioning. Clinical Cancer Research2015;21(14):3131-9. ">Baron 2015</a>; <a href="./references#CD009159-bbs2-0024" title="MoiseevIS , MorozovaEV , RudnizkayaYV , VlasovaYU , DarskayaEI , SlesarchukOA , et al. Update on the randomized trial of post-transplanation cyclophosphamide and rabbit ATG for graft-versus-host disease prophylaxis in chronic myeloproliferative neoplasms and myelodysplastic syndrome. Cellular Therapy and Transplantation2016;5(3):49‐50. ">Moiseev 2016</a>; <a href="./references#CD009159-bbs2-0027" title="RobinM , RajK , ChevretS , GauthierJ , deLavalladeH , MichonneauD , et al. Alemtuzumab versus anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. In: European Journal of Haematology. Vol. 30. 2018:30. ">Robin 2018</a>). </p> </li> <li> <p>Additional treatment differences besides ATG treatment in the intervention group were identified in one study (<a href="./references#CD009159-bbs2-0026" title="RamsayNK , KerseyJH , RobisonLL , McGlavePB , WoodsWG , KrivitW , et al. A randomized study of the prevention of acute graft-versus-host disease. New England Journal of Medicine1982;306(7):392-7. ">Ramsay 1982</a>). </p> </li> <li> <p>ATG was given in both treatment arms in five studies (<a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>; <a href="./references#CD009159-bbs2-0017" title="BashirQ , MunsellMF , GiraltS , dePadua SilvaL , SharmaM , CourielD , et al. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leukemia &amp; Lymphoma2014;53(5):915-9. ">Bashir 2014</a>; <a href="./references#CD009159-bbs2-0019" title="ChangY , WangY , MoXD , ZhangXH , XuLP , YanCH , et al. Optimal dose of antithymocyte globulin in conditioning regimens for unmanipulated haploidentical haematopoietic stem cell transplantation: Long-term outcomes of a prospective randomised trial. In: Blood. Vol. 128. 2016. ChangYJ , WangY , MoXD , ZhangXH , XuLP , YanCH , et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.[Erratum appears in Cancer. 2018 Feb 15;124(4):868; PMID: 29406585]. Cancer2018;123(15):2881-92. ">Chang 2018</a>; <a href="./references#CD009159-bbs2-0021" title="LinR , WangY , HuangF , FanZ , ZhangS , YangT , et al. Influence of lower dose antithymocyteglobulin as conditioning regimen on viral infection after haploidentical allogeneic stem cell transplantation. In: Blood. Vol. 128. 2016. LinR , WangY , HuangF , FanZ , ZhangS , YangT , et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC medicine2019;17(1):156. LinR , WangY , HuangF , FanZ , ZhangS , YangT , et al. Two doses of antithymocyteglobulin as graft-versus-host disease prophylaxis in haploidentical allogeneic stem cell transplantation:aa multicenter prospective study. In: Blood. Vol. 128. 2016. LinR , WangY , YangT , XuY , HuangF , FanZ , et al. EBV and CMV infection in recipients of haploidentical allogeneic stem cell transplantation receiving two different doses of antithymocyteglobulin as conditioning regimen. In: Haematologica. Vol. 101. 2016:629. ">Lin 2019</a>; <a href="./references#CD009159-bbs2-0028" title="WangY , FuHX , LiuDH , XuLP , ZhangXH , ChangYJ , et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplantation2014;49(3):426-33. WangY , Huang x. Influence of two different doses of antithymocyte globulin on clinical outcomes of leukemia patients following haploidentical hematopoietic stem cell transplantation: results of a randomized trial. In: Haematologica. Vol. 98. 2013:230. ">Wang 2014</a>). </p> </li> <li> <p>Three studies were randomised controlled trials with ATG in the intervention arm but more than 20 % of the patients were below 18 (<a href="./references#CD009159-bbs2-0018" title="ChamplinRE , PerezWS , PasswegJR , KleinJP , CamittaBM , GluckmanE , et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood2007;109(10):4582-5. ">Champlin 2007</a>; <a href="./references#CD009159-bbs2-0020" title="DoneyKC , WeidenPL , StorbR , ThomasED . Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation1981;31(2):141-3. ">Doney 1981</a>; <a href="./references#CD009159-bbs2-0029" title="WeidenPL , DoneyK , StorbR , ThomasED . Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation1979;27(4):227-30. WeidenPL , DoneyK , StorbR , ThomasED . Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplantation Proceedings1978;10(1):213-6. ">Weiden 1979</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009159-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>We evaluated risk of bias using the Cochrane risk of bias tool 1 (<a href="./references#CD009159-bbs2-0053" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:5928. [DOI: 10.1136/bmj.d5928] [PMID: 22008217]">Higgins 2011</a>).<br/>Randomisation was described in detail in all studies except for <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>. For the majority of studies allocation concealment was considered to be unclear, except (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>), which were considered to be low risk of bias. Blinding of patients and investigators was considered to be adequate except for three studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>), where the blinding process was unclear. Attrition bias was unclear in one study <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> and low in all others. We considered reporting bias to be unclear in four studies, due to unavailable study protocols to permit judgement of selective reporting (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). We considered other bias to be unclear in two studies, because the studies were stopped before the initial target sample was reached (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>). </p> <p>Overall risk of bias was judged to be low or unclear in the included 10 studies. We judged three studies to be of unclear risk of bias, with at least three domains being of unclear risk of bias (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). We considered the remaining seven studies to be low risk of bias. </p> <p>As most of the information is from trials at low risk of bias, the number of patients from studies with unclear risk of bias is small by comparison and therefore unlikely to introduce considerable amount of bias. Due to this reason we chose not to downgrade the available evidence, as well as separately analyse studies with unclear risk of bias.  A visual representation of risk of bias for each domain of the Cochrane risk of bias tool 1 is available in <a href="#CD009159-fig-0002">Figure 2</a>. Detailed information on each domain of the Cochrane risk of bias tool‐1 (<a href="./references#CD009159-bbs2-0053" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:5928. [DOI: 10.1136/bmj.d5928] [PMID: 22008217]">Higgins 2011</a>) for each of the included studies is provided in <a href="./references#CD009159-bbs1-0001" title="">Included studies</a>. </p> <div class="figure" id="CD009159-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD009159-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD009159-sec-0066"> <h4 class="title">Allocation</h4> <p>Randomisation sequences were described for all studies except for the study by <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>, which was considered to be of unclear risk as a consequence.<br/>Allocation concealment was described and considered to be of low risk of bias in three out of 10 included studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). <br/>The remaining seven studies did not provide any information and were considered to be unclear risk for selection bias (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>, <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). </p> </section> <section id="CD009159-sec-0067"> <h4 class="title">Blinding</h4> <p>Six studies used an open‐label design (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) . The study by <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> was double‐blinded. <br/>The potential strong and immediate adverse effects of ATG administration do not allow patient blinding. In addition, some investigated outcomes are less prone to detection bias than others.<br/>There was no information about blinding in three studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>), which we therefore considered as unclear risk regarding performance and detection bias. </p> </section> <section id="CD009159-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies analysed their primary outcomes using intention‐to‐treat analysis (<a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). Four studies provided a CONSORT study flow diagram to allow for comparison between the intervention and control group (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). Since the dropouts were low and comparable we considered these studies to be of low risk for attrition bias. </p> <p>The four remaining studies did not provide an intention‐to‐treat analysis or a study flow diagram, neither did they address participants lost to follow‐up or attrition (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). Three studies investigated survival and presented their findings as Kaplan Meyer curves. Since dropouts in the Kaplan Meyer curves lead to censorship of we considered attrition bias to be less of an issue (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>). As a consequence we considered these three studies to be of low risk for attrition bias. The study by <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> did not provide any description and was therefore considered to be of unclear risk of bias. </p> </section> <section id="CD009159-sec-0069"> <h4 class="title">Selective reporting</h4> <p>A study synopsis but not the complete protocol was available at http://www.controlled‐trials.com/mrct/ for the study by <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>. <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> reported the study protocol including the full set of outcomes at http://www.controlled‐trials.com/mrct/. Study protocols including some, but not all reported outcomes, were available at https://clinicaltrials.gov/ for four studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). We judged the reporting bias for these four studies as low risk. <br/>There was no protocol information available for the remaining three studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). A registry entry was available for <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> at https://cris.nih.go.kr, but it did not specify outcomes. We judged the reporting bias for these four studies were hence as unclear risk.<br/>In our investigation of publication bias we searched study registries for unpublished studies. We did not find studies resulting in unpublished literature, but three currently ongoing trials were identified (see <a href="./references#CD009159-bbs1-0003" title="">Ongoing studies</a>).<br/>Taking into consideration the availability of protocols for the included studies and the absence of completed studies which did not result in publications we estimate the risk of reporting bias overall as low. </p> </section> <section id="CD009159-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>In the studies by Bacigalupo (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>) two doses of ATG were compared in two sequential studies. Both studies terminated patient accrual before the targeted sample size was reached, the former because no significant effect was expected and the latter because the positive effect on severe acute GVHD would make continuation of the study unethical. A follow‐up publication (<a href="./references#CD009159-bbs2-0038" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5.">Bacigalupo 2006</a>) reported pooled patient data from both studies. As patient data of the former study was not separable and only patients surviving day 100 after transplantation were considered, we decided not to include this study in our data synthesis. </p> </section> </section> <section id="CD009159-sec-0071"> <h3 class="title" id="CD009159-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD009159-tbl-0001"><b>Summary of findings 1</b> ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</a> </p> <p>Different anti‐thymocyte globulin (ATG) preparations are available see <a href="#CD009159-tbl-0002">Table 1</a>. We included 10 randomised controlled studies (RCTs). The ATG preparations used in the studies considered are described in <a href="#CD009159-tbl-0004">Table 3</a>. The graft‐versus‐host disease (GVHD) prophylaxis and conditioning regimens used in the studies are shown in <a href="#CD009159-tbl-0005">Table 4</a> and <a href="#CD009159-tbl-0006">Table 5</a>.  The characteristics of the patients recruited in the studies are described in <a href="#CD009159-tbl-0007">Table 6</a>. Three ongoing studies which have not been published to date are identified <a href="#CD009159-tbl-0008">Table 7</a>. </p> <section id="CD009159-sec-0072"> <h4 class="title">Primary Outcomes</h4> <section id="CD009159-sec-0073"> <h5 class="title">Overall survival (OS)</h5> <p>Kaplan‐Meier plots or hazard ratios (HRs) regarding OS were available in 10 studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> provided no information on OS. 1249 patients were analysed and all patients received rabbit ATG. Different studies analysed OS at different time points, all the data were pooled for this study. The studies by <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> and <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> were used as lower and upper range for the calculation of hazard in the control groups, respectively.  </p> <p>Overall survival was probably not influenced by the addition of ATG for the prophylaxis of GVHD HR 0.93 (95 % confidence interval (C)I 0.77 to 1.13, 9 studies, n =1249, moderate‐certainty evidence) (<a href="./references#CD009159-fig-0003" title="">Analysis 1.1</a>). Heterogeneity amongst the nine trials was considered unimportant (Chi² = 11.42, df = 8 (P = 0.18); I² = 3 %).  </p> <p>Four studies reported OS data for one year (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) as a binary outcome; 506 patients were analysed and all patients received rabbit ATG. There is probably no effect with ATG on one‐year survival (risk ratio (RR) 0.87; 95 % CI 0.69 to 1.10) (<a href="./references#CD009159-fig-0004" title="">Analysis 1.2</a>). Heterogeneity amongst the four trials was considered unimportant (Chi² = 2.50, df = 3 (P = 0.48); I² = 0 %). </p> <p>Seven studies reported OS data for two years (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) as a binary outcome; 1035 patients were analysed and all patients received rabbit ATG. ATG probably does not influence two‐year survival (RR 1.01; 95 % CI 0.86 to 1.19). Heterogeneity amongst the seven trials was considered moderate (Chi² = 13.73, df = 6 (P = 0.03); I² = 56 %) (<a href="./references#CD009159-fig-0005" title="">Analysis 1.3</a>). </p> <p>Four studies reported OS data for three years (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>); 592 patients were analysed and all patients received rabbit ATG. ATG probably does not influence three‐year survival RR 0.89 (95 % CI 0.73 to 1.08). Heterogeneity amongst the four trials was considered unimportant (Chi² = 1.98, df = 3 (P = 0.58); I² = 0 %) (<a href="./references#CD009159-fig-0006" title="">Analysis 1.4</a>). </p> <section id="CD009159-sec-0074"> <h6 class="title">Subgroup analysis</h6> <p>We did not identify relevant subgroup differences for the following subgroups: ATG‐F and thymoglobulin. </p> <p> <ul id="CD009159-list-0017"> <li> <p>ATG‐F HR 1.10 (95 % CI 0.82 to 1.46, 3 studies) vs thymoglobulin HR 0.89 (95 % CI 0.68 to 1.15, 5 studies). Test for subgroup differences: Chi² = 1.16, df = 1 (P = 0.28), I² = 14.0 %. (<a href="./references#CD009159-fig-0007" title="">Analysis 1.5</a>).  </p> </li> <li> <p>Low‐dose ATG‐F (≤ 30 mg) HR 1.48 (95 % CI 0.97 to 2.25, 2 studies) versus high‐dose ATG‐F (&gt; 30 mg) HR 0.84 (95 % CI 0.56 to 1.25, 1 study). Test for subgroup differences: Chi² = 3.66, df = 1 (P = 0.06), I² = 72.7 %. (<a href="./references#CD009159-fig-0008" title="">Analysis 1.6</a>).  </p> </li> <li> <p>Low‐dose thymoglobulin ≤ 4.5 mg HR 0.88 (95 % CI 0.64 to1.22, 3 studies) was compared to high‐dose &gt; 4.5 mg HR 0.90 (95 % CI 0.58 to 1.39, 3 studies). Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.95), I² = 0 %. (<a href="./references#CD009159-fig-0009" title="">Analysis 1.7</a>). </p> </li> <li> <p>Matched siblings HR 0.98 (95 % CI 0.71to 1.34, 4 studies) and unrelated donors HR 1.07 (95 % CI 0.81 to 1.40, 4 studies). Test for subgroup differences: Chi² = 0.16, df = 1 (P = 0.69), I² = 0 %. (<a href="./references#CD009159-fig-0010" title="">Analysis 1.8</a>).  </p> </li> </ul> </p> </section> </section> </section> <section id="CD009159-sec-0075"> <h4 class="title">Secondary Outcomes</h4> <section id="CD009159-sec-0076"> <h5 class="title">1. Acute: graft‐versus‐host disease (GVHD)</h5> <section id="CD009159-sec-0077"> <h6 class="title">a. Acute GVHD grade II to IV </h6> <p>Data on 1413 patients with acute GVHD grades II to IV were available from all 10 studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). ATG results in a reduction of acute GVHD relative risk (RR) 0.68 (95 % CI 0.60 to 0.79, 10 studies, n=1413, high‐certainty evidence) (<a href="./references#CD009159-fig-0011" title="">Analysis 2.1</a>). Heterogeneity between the studies was considered moderate (Chi² = 16.05, df = 9 (P = 0.07); I² = 44 %).  </p> <section id="CD009159-sec-0078"> <p><b>Subgroup analysis</b></p> <p>We did not identify relevant subgroup differences for the following subgroups.</p> <p> <ul id="CD009159-list-0018"> <li> <p>ATG‐F RR 0.59 (95 % CI 0.47 to 0.74, 4 studies) versus thymoglobulin RR 0.76 (95 % CI 0.64 to 0.91, 6 studies). Test for subgroup differences: Chi² = 3.09, df = 1 (P = 0.08), I² = 67.6 %.  (<a href="./references#CD009159-fig-0012" title="">Analysis 2.2</a>).  </p> </li> <li> <p>Low‐dose ATG‐F (≤ 30 mg) RR 0.57 (95 % CI 0.40 to 0.80, 2 studies) versus high‐dose ATG‐F (&gt; 30 mg) RR 0.61 (95 % CI 0.45 to 0.82, 2 studies). Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.77), I² = 0 %. (<a href="./references#CD009159-fig-0013" title="">Analysis 2.3</a>). </p> </li> <li> <p>Low‐dose thymoglobulin ≤ 4.5 mg RR 0.76 (95 % CI 0.61 to 0.94, 3 studies) was compared to high‐dose &gt; 4.5 mg RR 0.77 (95 % CI 0.58 to 1.02, 3 studies). Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.93), I² = 0 %.  (<a href="./references#CD009159-fig-0014" title="">Analysis 2.4</a>). </p> </li> <li> <p>Matched siblings RR 0.76 (95 % CI 0.56 to 1.04, 4 studies) and unrelated donors RR 0.62 (95 % CI 0.51 to 0.75, 5 studies). Test for subgroup differences: Chi² = 1.33, df = 1 (P = 0.25), I² = 24.7 % (<a href="./references#CD009159-fig-0015" title="">Analysis 2.5</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009159-sec-0079"> <h6 class="title">b. Acute GVHD grade III to IV </h6> <p>Data on 10 studies were available for this analysis with 1346 patients (<a href="./references#CD009159-fig-0016" title="">Analysis 2.6</a>). Prophylactic ATG decreases acute GVHD grade III to IV RR 0.62 (95 % CI 0.48 to 0.81). There was moderate heterogeneity amongst the studies (Chi² = 15.3, df = 9 (P = 0.08); I² = 41 %).  </p> </section> </section> <section id="CD009159-sec-0080"> <h5 class="title">2. Chronic GVHD</h5> <section id="CD009159-sec-0081"> <h6 class="title">a. Overall chronic GVHD</h6> <p>Eight studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) analysing 1273 patients provided data on overall chronic GvHD in <a href="#CD009159-tbl-0009">Table 8</a>. The addition of ATG to GVHD prophylaxis reduces the risk of developing chronic GVHD (RR 0.53; 95 % CI 0.45 to 0.61, 8 studies, n=1273, high‐certainty evidence) (see <a href="./references#CD009159-fig-0017" title="">Analysis 3.1</a>.). There was considerable heterogeneity between the studies (Chi² = 38.84, df = 7 (P &lt; 0.00001); I² = 82 %).  </p> <div class="table" id="CD009159-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Chronic GVHD</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median follow‐up (rounded)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall chronic GHVD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Limited chronic GVHD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Extensive chronic GVHD</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 20 (40 %)<br/>Control: N = 13 of 20 (65 %), (P = 0.08) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 7 of 18 (39 %)<br/>Control: N = 10 of 17 (59 %), (P = 0.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG group 250 days(150‐440)</p> <p>Control group 440 days (300‐1095 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:35.5%</p> <p>Control:77.5%</p> <p>P=&lt;0.0000001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 27 of 90 (30 %)<br/>Control: N = 47 of 80 (59 %) </p> <p>(P &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 16 of 90 (18 %)<br/>Control: N = 13 of 80 (16 %), </p> <p>(P = NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 11 of 90 (12 %)<br/>Control: N = 34 of 80 (43 %), </p> <p>(P &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 22 (26.5 %)</p> <p>Control: 46 (63.9 %)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 17 (20.5 %)</p> <p>Control: 22 (30.6 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 5 (6 %)</p> <p>Control: 24 (33.3 %)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:22 % (15‐31)</p> <p>Control:33 % (24‐43)</p> <p>P=0.065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 13 % (13)<br/>Control 29 % (28) </p> <p>P=0.0083</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIH criteria</p> <p>ATG: 16 % (9.7‐24)</p> <p>Control: 38 % (29‐47)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIH criteria Moderate‐severe</p> <p>ATG: 12 % (6.7‐19)</p> <p>Control: 33 % (25‐42)</p> <p>P&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,163 days (range 182‐2027 days) post transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 27.9 % (27.6‐28.2)</p> <p>Control: 52.2 % (52.1‐52.9)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 8.5 (8.4‐8.6)<br/>Control: 23.2 (22.9‐23.5) </p> <p>P=0.029</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 months (874 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 37.5 %</p> <p>Control 52.5% p=&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 9.5 %</p> <p>Control 20 %</p> <p>P=0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 19.8 %</p> <p>Control 38.4 % p=0.060</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 25% Control 65.4% p=&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Results were extracted from long term follow‐up (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>): NR‐ Not reported, NIH National Institute of health </p> </div> </div> <p>In a sensitivity analysis the exclusion of <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> removed the considerable heterogeneity, but did not have a large effect on the overall estimate due to the low weight of this study (RR 0.49; 95 % CI 0.42 to 0.57; 7 studies, high‐certainty evidence) (Heterogeneity Chi² = 4.76, df = 6 (P = 0.57); I² = 0 %). Due to this reason the certainty was considered to be high, despite the observed heterogeneity in the overall analysis. </p> <section id="CD009159-sec-0082"> <p><b>Subgroup analysis</b></p> <p>We did not identify relevant subgroup differences for the following subgroups, except for Low‐dose ATG vs high‐dose ATG, as described below. </p> <p> <ul id="CD009159-list-0019"> <li> <p>ATG‐F RR 0.52 (95 % CI 0.43‐ 0.64, 4 studies) versus thymoglobulin RR 0.53 (95 % CI 0.43 to 0.65, 4 studies). Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.94), I² = 0 %. (<a href="./references#CD009159-fig-0018" title="">Analysis 3.2</a>)  </p> </li> <li> <p>Low‐dose ATG‐F (≤ 30 mg) RR 0.42 (95 % CI 0.31to 0.57, 2 studies) versus high‐dose ATG‐F (&gt; 30 mg) RR 0.68 (95 % CI 0.52 to 0.87, 2 studies). Test for subgroup differences: Chi² = 5.56, df = 1 (P = 0.02), I² = 82.0 %. (<a href="./references#CD009159-fig-0019" title="">Analysis 3.3</a>) </p> </li> <li> <p>Low‐dose thymoglobulin ≤ 4.5 mg 0.54 RR (95 % CI 0.43 to 0.68, 3 studies) was compared to high‐dose &gt; 4.5 mg RR 0.43 (95 % CI 0.22 to 0.85, 1 study). Test for subgroup differences: Chi² = 0.40, df = 1 (P = 0.53), I² = 0 %. (<a href="./references#CD009159-fig-0020" title="">Analysis 3.4</a>).  </p> </li> <li> <p>Matched siblings RR 0.47 (95 % CI 0.38‐ 0.58, 4 studies) and unrelated donors RR 0.59 (95 % CI 0.48 to 0.72, 4 studies). Test for subgroup differences: Chi² = 2.26, df = 1 (P = 0.13), I² = 55.7 %. (<a href="./references#CD009159-fig-0021" title="">Analysis 3.5</a>).  </p> </li> </ul> </p> <p>Two studies provided data for ATG‐F low dose (≤ 30 mg) and two studies for ATG‐F high dose (&gt; 30 mg). For ATG‐F low versus high dose we observed a difference in subgroups pointing towards a benefit with the lower dose of ATG‐F (P = 0.02), while both doses of ATG reduce chronic GVHD when compared to placebo.However, considerable heterogeneity in the high‐dose subgroup needs to be considered (I<sup>2=</sup> = 82 %), as well as the low number of participants, as well as studies per group, hence we advise caution in the interpretation of these results (<a href="./references#CD009159-fig-0019" title="">Analysis 3.3</a>).  </p> </section> </section> <section id="CD009159-sec-0083"> <h6 class="title">b. Limited chronic GVHD</h6> <p>Three studies reported limited chronic GvHD (<a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>).  <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> provided GvHD information based on the Seattle criteria and not <b>:</b> National Institutes of Health (NIH) classification. Hence, the data could not be included in this analysis; 397 patients were analysed. ATG probably decreased limited GVHD (RR 0.77; 95 % CI 0.52 to 1.14); low heterogeneity Chi² = 1.95, df = 2 (P = 0.38); I² = 0 % (<a href="./references#CD009159-fig-0022" title="">Analysis 3.6</a>). No further subgroup analysis was performed due to lack of data.  </p> </section> <section id="CD009159-sec-0084"> <h6 class="title">c. Extensive chronic GVHD</h6> <p>Six studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>;<a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>) provided data on 735 patients with extensive chronic GvHD. <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> provided GvHD information based on the Seattle criteria and not NIH classification. Hence, the data could not be included in this analysis. ATG probably decreases extensive chronic GVHD (RR 0.33; 95 % CI 0.25 to 0.45). There was moderate to substantial heterogeneity amongst the individual groups (Chi² = 9.52, df = 5 (P = 0.09); I² = 47 %)(<a href="./references#CD009159-fig-0023" title="">Analysis 3.7</a>). Sensitivity analysis did not reduce the observed heterogeneity below I<sup>2</sup> of 34 %. </p> </section> </section> <section id="CD009159-sec-0085"> <h5 class="title">3. Incidence of relapse</h5> <p>Eight studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) comprising 1315 patients reported on the incidence of relapse. Details about the incidence of relapse are summarised in <a href="#CD009159-tbl-0010">Table 9</a>. The addition of ATG probably increases slightly the incidence of relapse ((RR 1.21; 95 % CI 0.99 to 1.49), eight studies, n=1315, moderate‐certainty evidence) (<a href="./references#CD009159-fig-0024" title="">Analysis 4.1</a>). Heterogeneity was considered unimportant (Chi² = 9.21, df = 7 (P = 0.24); I² =24 %).  </p> <div class="table" id="CD009159-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Incidence of relapse</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of</b> </p> <p><b>evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relapse</b> </p> <p><b>ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relapse</b> </p> <p><b>Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>HR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 /29 (10 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 /25 (12 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/27 (36 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 /28 (18 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34/103 (32.6 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 /98 (28.2 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 32.2 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 25.5 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 11 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 32 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 21 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 20.8 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 15.4 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.362</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6/42) 23.1 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(10/30) 36.5 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.078</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 20 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 9.3 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.055</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Results were extracted from long term follow‐up (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>): NR‐ not reported, NNR‐number not reported </p> </div> </div> <section id="CD009159-sec-0086"> <h6 class="title">Subgroup analysis</h6> <p>We did not identify relevant subgroup differences for the following subgroups, except for low‐dose versus high‐dose thymoglobulin. </p> <p> <ul id="CD009159-list-0020"> <li> <p> ATG‐F RR 1.31 (95 % CI 1.01 to 1.69, 3 studies) vs thymoglobulin RR 1.09 (95 % CI 0.79 to 1.52, 5 studies). Test for subgroup differences: Chi² = 0.71, df = 1 (P = 0.40), I² = 0 %. (<a href="./references#CD009159-fig-0025" title="">Analysis 4.2</a>).  </p> </li> <li> <p>Low‐dose ATG‐F (≤ 30 mg) RR 1.40 (95 % CI 1.01 to 1.95, 2 studies) versus high‐dose ATG‐F&gt; 30 mg RR 1.16 (95 % CI 0.76 to 1.75, one study). Test for subgroup differences: Chi² = 0.52, df = 1 (P = 0.47), I² = 0 %. (<a href="./references#CD009159-fig-0026" title="">Analysis 4.3</a>).  </p> </li> <li> <p>Low‐dose thymoglobulin ≤ 4.5 mg RR 1.30 (95 % CI 0.90 to 1.87, 3 studies) was compared to high‐dose thymoglobulin &gt; 4.5 mg RR 0.52 (95 % CI 0.24 to1.12). Test for subgroup differences: Chi² = 4.42, df = 1 (P = 0.04), I² = 77.4 %<b>.</b> (<a href="./references#CD009159-fig-0027" title="">Analysis 4.4</a>) </p> </li> <li> <p>Matched siblings RR 1.21 (95 % CI 0.89 to 1.66, 4 studies) and unrelated donors RR 1.21 (95 % CI 0.93 to 1.58, 4 studies). Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0 % (<a href="./references#CD009159-fig-0028" title="">Analysis 4.5</a>). </p> </li> </ul> </p> <p>A subgroup difference was observed for the subgroups based on thymoglobulin dose. Our results suggest an advantage for high‐dose compared to low‐dose thymoglobulin regarding Incidence of relapse (Chi = 4.42, df = 1 (P = 0.04); I<sup>2</sup> = 77.4 %), while both doses of thymoglobulin reduce GVHD when compared to placebo in this analysis. Due to the high heterogeneity in this group these results need to be interpreted with caution (<a href="./references#CD009159-fig-0027" title="">Analysis 4.4</a>).  </p> </section> </section> <section id="CD009159-sec-0087"> <h5 class="title">4. Non‐relapse mortality (NRM)</h5> <section id="CD009159-sec-0088"> <h6 class="title">a. NRM (time to event)</h6> <p>Kaplan‐Meier plots or hazard ratios (HRs) reported data on NRM in nine studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) including 1370 patients. Details of all studies are summarised in <a href="#CD009159-tbl-0011">Table 10</a>. Non relapse mortality was probably not influenced by ATG ((HR 0.86 (95 % CI 0.67 to 1.11) nine studies, n=1370, moderate‐certainty evidence) (<a href="./references#CD009159-fig-0029" title="">Analysis 5.1</a>). Heterogeneity was considered to be unimportant (Chi² = 5.08, df = 8 (P = 0.75); I² = 0 %).  </p> <div class="table" id="CD009159-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Non‐relapse mortality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall non‐relapse mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mortality from GVHD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mortality from Infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Non‐relapse mortality from other causes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:12/ 29 (42%) <br/>Control: 10/ 25 (40%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 29 (28%)<br/>Control: N = 8 of 25 (32%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 2/29 (7%)<br/>Control: 2/25 (8%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 2 of 29 (7%)<br/>Control: N = 0 of 25 (0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other causes include: Multi‐organ failure.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 11/27 (41%)<br/>Control: 14/28 (50%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 3 of 27 (11%)<br/>Control: N = 11 of 28 (39%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 8 /27 (30%)<br/>Control: 2 /28 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 0 of 27 (0%)<br/>Control: N = 1 of 28 (4%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other causes include: Multi‐organ failure.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients died in the control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years post‐transplant:</p> <p>ATG: 20/ 103 (19.6%)<br/>Control:28/ 98 (28.9%), HR 0.68 (95% CI 0.38 to 1.22, P = 0.20) </p> <p>3 years post‐transplant:**</p> <p>ATG: 20 /103 (19%)<br/>Control: 33/98 (34%), HR = 0.68 (P = 0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 1 of 103 (1%)<br/>Control: N = 13 of 98 (13%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 103 (8%)<br/>Control: N = 7 of 98 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 11 of 103 (11%)<br/>Control: N = 9 of 98 (9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up for overall non‐relapse mortality is 2 and 3 years, for details it is 2 years. Other causes include: Graft failure, interstitial pneumonia, multi‐organ failure and other causes occurring less than once. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:14%</p> <p>Control:12%</p> <p>P=0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:23%</p> <p>Control:24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG.21%</p> <p>Control:13.5%</p> <p>P=0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:9.9%</p> <p>Control:14.3%</p> <p>P=0.552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:3%</p> <p>Control:5.3%</p> <p>P=0.345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 6% 8/132</p> <p>Controls: 6.8% 9/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 2.2%</p> <p>Control: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall 14%</p> <p>ATG:13%</p> <p>Control:8.5%</p> <p>P=0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients in ATG group and 1 in control died of respiratory failure. 1 patient in ATG group died of gastrointestinal haemorrhage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 10%</p> <p>Control 17.5%</p> <p>P=0.330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Numbers of patients with mortality from GVHD were obtained by personal communication with the authors. </p> <p>** 3‐year overall NRM was reported in a long‐term follow‐up publication (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>). </p> </div> </div> <section id="CD009159-sec-0089"> <p><b>Subgroup analysis</b></p> <p>We did not identify relevant subgroup differences for the following subgroups: </p> <p> <ul id="CD009159-list-0021"> <li> <p>ATG‐F HR 0.95 (95 % CI 0.65 ‐ 1.40, 3 studies) versus thymoglobulin HR 0.84 (95 % CI 0.60 to 1.18, 6 studies). Test for subgroup differences: Chi² = 0.24, df = 1 (P = 0.62), I² = 0 % (<a href="./references#CD009159-fig-0030" title="">Analysis 5.2</a>).  </p> </li> <li> <p>Low‐dose ATG‐F ≤ 30 mg HR 1.23 (95 % CI 0.74 to 2.04, 2 studies) versus high‐dose ATG‐F &gt; 30 mg HR 0.68 (95 % CI 0.38 to 1.22, one study). Test for subgroup differences: Chi² = 2.27, df = 1 (P = 0.13), I² = 56.0 % (<a href="./references#CD009159-fig-0031" title="">Analysis 5.3</a>). </p> </li> <li> <p>Low‐dose thymoglobulin ≤ 4.5 mg HR 0.73 (95 % CI 0.47 to 1.13, 3 studies) was compared to high‐dose &gt; 4.5 mg HR 1.03 (95 % CI 0.60 to 1.76, 3 studies). Test for subgroup differences: Chi² = 0.96, df = 1 (P = 0.33), I² = 0 %.(<a href="./references#CD009159-fig-0032" title="">Analysis 5.4</a>) </p> </li> <li> <p>Matched siblings HR 0.87 (95 % CI 0.54 to 1.40, 4 studies) and unrelated donors HR 0.93 (95 % CI 0.66 to 1.30). Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.83), I² = 0 % (<a href="./references#CD009159-fig-0033" title="">Analysis 5.5</a>).  </p> </li> </ul> </p> </section> </section> <section id="CD009159-sec-0090"> <h6 class="title">b. NRM (binary outcome)</h6> <p>NRM was also investigated as a binary outcome in nine studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) including 1370 patients. The RR was 0.83 (95 % CI 0.67 to 1.03) (see <a href="./references#CD009159-fig-0034" title="">Analysis 5.6</a>). The results point towards a lower risk of NRM in the ATG‐treated patients. Heterogeneity was considered to be unimportant (Chi² = 9.68, df = 8 (P = 0.29); I² = 17 %). A drawback of this analysis is the inclusion of varying time points. One study reported 1 year NRM (<a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>), six studies reported two‐year NRM (<a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>), and two studies reported three‐year NRM (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>). The discordant data limits the analysis of these data.  </p> </section> <section id="CD009159-sec-0091"> <h6 class="title">c. NRM regarding GVHD (binary outcome)</h6> <p>NRM regarding chronic GVHD was investigated in five studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>) including 645 patients. ATG may reduce NRM regarding chronic GVHD (RR 0.35; 95 % CI 0.20 to 0.60) (<a href="./references#CD009159-fig-0035" title="">Analysis 5.7</a>). Moderate heterogeneity was present between the studies (Chi² = 7.16, df = 3 (P = 0.07); I² = 58 %). </p> </section> <section id="CD009159-sec-0092"> <h6 class="title">d. NRM regarding infection (binary outcome)</h6> <p>NRM regarding infection was investigated in three studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>) including 310 patients.  ATG may increase NRM regarding infection (RR 1.58; 95 % CI 0.78 to 3.21) (<a href="./references#CD009159-fig-0036" title="">Analysis 5.8</a>). Heterogeneity was considered to be unimportant (Chi² = 2.65, df = 2 (P = 0.27); I² = 24 %). </p> </section> </section> <section id="CD009159-sec-0093"> <h5 class="title">5. Graft failure</h5> <p>Eight studies provided data for graft failure (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>, <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). There were only 13 events in 1240 patients. ATG intervention may result in no increase in graft failure ((RR 1.55; 95 % CI 0.54 to 4.44), eight studies, n=1240, low‐certainty evidence) (<a href="./references#CD009159-fig-0037" title="">Analysis 6.1</a>). Heterogeneity was considered to be unimportant Chi² = 2.52, df = 3 (P = 0.47); I² = 0 %. </p> <p>No subgroup analyses were carried out due to the overall low number of events.</p> <p>Details of the engraftment data are summarised in <a href="#CD009159-tbl-0012">Table 11</a>. </p> <div class="table" id="CD009159-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Engraftment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of engraftment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Result ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Result control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary graft failure ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary graft failure Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with neutrophil counts ≥ 0.5 x 10/L (%), time of evaluation not mentioned.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 of 29 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 of 25 (84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil count of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 18 (13 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 17 (13 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with neutrophil counts ≥ 0.5 x 10/L (%) time of evaluation not mentioned.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 of 29 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 of 28 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil count of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (13 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (14 to 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from transplantation (day 0) to the first day of achieving an absolute neutrophil count of ≥ 0·5 × 10/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12(8‐21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/19 (94.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/24 (95.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil counts of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 24 (range 3 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 17 (range 10 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil counts of 1.0 x 10^9/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 26 (range 3 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (range 12 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Engraftment with neutrophils ≥ 1.0 × 10/L at day 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 of 103 (97.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 of 98 (94.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment≥0.5×10<sup>9</sup>/L) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18(10‐31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15(11‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet count of ≥ 20 × 10⁹/ L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20(10‐110)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(6‐29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from transplantation (day 0) to the first day of achieving an absolute neutrophil count of ≥ 0·5 × 10/L for three consecutive measurements on different days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (14‐22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (13‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from day 0 to the first day of achieving a platelet count of ≥ 20 × 10⁹/ L for three consecutive measurements on different days without needing platelet transfusions in the previous 7 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (13‐27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5 (12.5‐23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment was defined as the first of 3 consecutive days of absolute neutrophil count&gt;0.5x10<sup>9</sup>/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24(5‐45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19(8‐41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4% n= 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8% n=1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet engraftment was defined as the first of 3 consecutive days with self‐supported platelet counts &gt;20x 10<sup>9</sup>/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (6‐205)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19(5‐45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count &gt;0.5 x 10<sup>9</sup>/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (9‐24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(8‐23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet engraftment was defined as the first of 7 consecutive days with a platelet count &gt;20 x 10<sup>9</sup>/L without transfusion dependence. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (8‐68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment is day of achieving an absolute neutrophil count of ≥ 0·5 × 10<sup>9</sup>/L for three consecutive days. </p> <p>Platelet engraftment &gt;20x 10<sup>9</sup>/L for 7 consecutive days without transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12(8‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil and platelet engraftment was defined as an absolute neutrophil count of &gt; 0.5 10<sup>9</sup>/L during the first of three consecutive days or a platelet count of &gt; 20x10<sup>9</sup>/L without transfusion support during the first of seven consecutive days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 12 (7–23)</p> <p>Platelet count: 14 (9–30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 12 (7–25)</p> <p>Platelet count: 12 (5–35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 0.902</p> <p>Platelet count: 0.414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>All patients engrafted in the studies by Finke (<a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>) and Chang (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>). Walker (<a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) analysed engraftment only for 66 patients in both group who received myeloablative conditioning </p> </div> </div> </section> <section id="CD009159-sec-0094"> <h5 class="title">6. Adverse events</h5> <p>Adverse events were not reported in detail in all the articles. Due to the lack of data a meta‐analysis could not be performed on this end point. Instead, the results are detailed below as a narrative summary. </p> <p>Six studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) did not report adverse events. <br/><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> observed an increase in &gt; grade 2 infusion related reactions related to the study drug (39 % in the treatment arm versus 0 % in the control arm). <br/><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> reported infusion‐related side effects but no other adverse events. </p> <p>In the study by <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>,all patients observed at least one adverse event and both treatment groups were similar except for chills, which were more frequent in the ATG group (n = 33, 31.1 %) than in the control group (n = 13, 13.7 %). Serious adverse events were comparable in both groups (ATG‐F n = 81, 76.4 % versus Control n = 62, 65.3 %). Three cases of anaphylactic shock occurred in the treatment arm. <br/><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> reported no difference between treatments arms regarding occurrence of adverse events. 394 versus 344 overall and 89 versus 55 serious adverse events were observed in the ATG (n = 86) and in the control (n = 75) arm respectively. <br/><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> observed no differences in the occurrence of serious adverse events between patients in the ATG (n = 34/99, 34 %) and control group (n = 41/97, 42 %). No differences were observed between both arms of the trial with regard to adverse events in three studies (<a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>).  </p> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> reported an increased risk of adverse events in the ATG group. 39 versus 2 adverse events and 9 versus 0 severe adverse events were reported in the ATG group (n = 128) and the control arm (n = 132), respectively. This is in contrast to the observations by the other studies. </p> </section> <section id="CD009159-sec-0095"> <h5 class="title">7. New outcomes in this review update</h5> <p>Quality of life and the incidence of infection are outcomes which are of interest from the clinical point of view. The addition of ATG is performed with the intention to reduce the risk of GVHD which thereby probably increases the quality of life and reduces the incidence of infections. Hence, these two outcomes were analysed in addition. </p> <section id="CD009159-sec-0096"> <h6 class="title">7.1. Quality of life </h6> <p>Quality of life was reported in the studies by <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> and <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>. <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> handed out six different questionnaires at two different time points, six and 12 months. At 12 months the chronic GVHD group showed a significant difference in the quality of life on the Lee scale.  <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> used the Karnofsky performance score to analyse quality of life and defined a score above 80 as high quality of life and below 60 as low or poor quality of life. 2/19 patients had a score above 80. The data from these two trials were not comparable, therefore we did not perform a meta‐analysis.  </p> </section> <section id="CD009159-sec-0097"> <h6 class="title">7.2. Incidence of infections</h6> <p>Seven studies provided information regarding infections (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>). Reporting on infections was not uniform across the studies. Due to lack of congruent data a meta‐analysis could not be performed. Instead, results are presented as a narrative summary. </p> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> reported no differences in cytomegalovirus (CMV) reactivation at day 100, epstein Barr virus (EBV) reactivation at day 180, blood stream infection (BSI) at day 30 and invasive fungal disease (IFD) between the ATG and control arms of the study.  </p> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> reported an increase in EBV reactivation (≥1000 international units (IU)/mL) in the ATG group compared to the control group. No differences were observed between ATG and control group regarding CMV DNA levels, CMV disease, bacterial sepsis, fungal infection, pulmonary infection, herpes zoster and Hepatitis B Virus (HBV) reactivation by them. </p> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> reported no difference in CMV reactivation between the ATG and control arm.  The authors observed a higher rate of EBV reactivation in the ATG arm in contrast to fungal infections which were significantly lower in ATG arm. No cases of post transplant lymphoproliferative disorders were observed in either group. <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> reported no differences in the incidence of infectious complications, CMV reactivations, EBV reactivations or fungal infections between the ATG and control arm.  </p> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> reported data on the incidence of bacterial, viral, fungal infections or those caused by a non‐identified organism. The incidence of infections was defined as the proportion of patients experiencing at least one infection. Data were reported for the 'safety population' of each treatment group, that is every patient in the ATG safety population really received ATG, and vice versa, in contrast to the 'per‐protocol' population. Almost every patient in each group experienced at least one infection. Results were similar for overall infections and bacterial infections for both groups. Viral infections occurred more often in the ATG group (ATG 74.5 % versus control 64.2 %) as well as infections by non‐identified organisms (ATG 83 % versus control 70.5 %). </p> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> reported that the incidence of serious infections (reactivation of EBV or CMV) did not differ between ATG and control group. The authors provide an extensive list with percentages for several causes of serious infections. Most of these infection rates appear similar for both groups. Despite the lack of P values there seems to be a considerable difference in the rate of underlying EBV infections when comparing ATG with the control group (33 and 3 %). </p> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> reported one case of severe lung infection, but it is unclear which group the patient belonged to. In addition, 5 cases in their control group required hospitalisation due to weight loss, liver damage and lung infection. </p> <p>The details of the described infection rates are summarised in <a href="#CD009159-tbl-0013">Table 12</a>. </p> <div class="table" id="CD009159-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Infections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall incidence of Infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bacterial infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Viral infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fungal infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Infection prophylaxis:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall viral infections not reported,</p> <p>CMV reactivation rate:</p> <p>ATG: 83%; control 88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciprofloxacin, Fluconazole, high‐dose immunoglobulins, acyclovir (foscarnet instead in one of four centres) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall viral infections not reported,</p> <p>CMV reactivation rate:</p> <p>ATG: 67%; control 78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciprofloxacin, Fluconazole, high‐dose immunoglobulins, acyclovir (foscarnet instead in one centre) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 104 of 106 (98%)<br/>Control: 92 of 95 (97%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 66 of 106 (62%)<br/>Control: 65 of 95 (68%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 79 of 106 (75%)<br/>Control: 61 of 95 (64%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 35 of 106 (33%)<br/>Control: 36 of 95 (38%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported, "Supportive care was done according to centre‐specific standards."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 48 of 83 (58%)<br/>Control: 39 of 72 (54%) (P = 0.65). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary infection:<br/>ATG: 6 of 83 (7%)<br/>Control: 10 of 72 (14%) (p=0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation:<br/>ATG: 18/83 (22%)<br/>Control: 18/72(25%)<br/>P=0.63) </p> <p>EBV reactivation:<br/>ATG 3/83 (4%)<br/>Control: 1/72(1%) (p=0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 3/83 (4%)<br/>Control: 3/72 (4%)<br/>(p=0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any infection:<br/>ATG: 42/99 (42%)<br/>Control: 37/97 (38%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clostridium difficile:<br/>ATG: 2/99 (3%)<br/>Control: 3/97 (5%) </p> <p>Escherichia coli bacteria:<br/>ATG: 0/99 (%)<br/>Control: 2/97 (3%) </p> <p>Other bacteria:<br/>ATG: 11/99 (18%)<br/>Control: 20/97 (32%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epstein‐Barr virus:<br/>ATG: 20/99 (33%) Control: 2/97 (3%) </p> <p>Adenovirus:<br/>ATG: 2/99 (3%)<br/>Control: 2/97 (3%) </p> <p>CMV:<br/>ATG: 5/99 (8%)<br/>Control: 5/97 (8%) </p> <p>Other viruses:<br/>ATG: 6 /99 (10%)<br/>Control: 6 /97 (10%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fungal:<br/>ATG: 3/99 (5%)<br/>Control: 4/97 (7%) </p> <p>Protozoal<br/>ATG: 1/99 (2%)<br/>Control: 0/97 (0%)<br/>Multiple organisms:<br/>ATG: 3/99 (5%)<br/>Control: 4/97 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSI at day 30:<br/>ATG: 4% (3.0 ‐ 4.6)<br/>Control: 3% (3.0 ‐ 3.2) (P=0.769) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation at day 100:<br/>ATG: 23% (22.4‐23.0)<br/>Control: 24% (23.6 ‐ 24.2) (P =0.674) </p> <p>EBV reactivation at day 180:<br/>ATG: 8% (7.7 ‐7.9) <br/>Control: 3% (3.3‐3.5) (P = 0.289) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFD at 1 year:<br/>ATG: 14% (13.5 ‐ 13.9) <br/>Control: 14% (13.6‐14.0) (P = 0.843) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 26 /42 (62%)<br/>Control: 21/30 of 72 (70%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation:<br/>ATG: 11/42 (26%)<br/>Control: 6/30(20%)<br/>P=0.587 </p> <p>EBV reactivation:<br/>ATG11/42 (26%)<br/>Control: 2/30(7%) (p=0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 4/42 (10%)<br/>Control: 13/30 (43%) </p> <p>P=0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 10/60 (17%)</p> <p>Control 8/60(13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EBV reactivation ATG 22%: Control 5%, CMV disease ATG 5%: Control 12%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR‐ Not reported, BSI‐ Bacterial super infections, IFD‐ Invasive fungal disease, CMV‐ cytomegalovirus, EBV‐ Epstein Barr virus </p> </div> </div> <p><b>The summary of all the major outcomes and grade outcomes are shown in the summary of findings table</b>. <a href="./full#CD009159-tbl-0001">summary of findings Table 1</a>.  We compared our data from other systematic reviews in <a href="#CD009159-tbl-0014">Table 13</a> </p> <div class="table" id="CD009159-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Comparison of contemporary systematic review analyses</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>This review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009159-bbs2-0057" title="KumarA , ReljicT , HamadaniM , MohtyM , Kharfan-DabajaMA . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplantation2019;54(7):1094-106."><b>Kumar 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009159-bbs2-0035" title="AraiY , JoT , MatsuiH , KondoT , Takaori-KondoA . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukaemia and Lymphoma2017;58(8):1840-8."><b>Arai 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0046" title="GagelmannN , AyukF , WolschkeC , KrogerN . Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biology of Blood &amp; Marrow Transplantation2017;23(12):2184-91.">Gagelmann 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐(Excluding <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>, Including <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (Included <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>; Excluded <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (Included <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>, excluded </p> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (Excluded <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total no of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>871</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.93 (95% CI 0.77 to 1.13; P=0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.97(95% CI 0.74 to 1.28, P=0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.85 (95% CI 0.63 to 1.13; P=0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG RR 1.2 (95% CI 0.95 to 1.52)</p> <p>Thymoglobulin RR 0.99 (0.84 to 1.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute GvHD</p> <p>Grades 2‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.68 (95% CI 0.60 to 0.79; P = &lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.61(95% CI 0.48 to 0.77; P&lt;0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (95% CI 0.52 to 0.94; P=0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 0.54 (95% CI 0.39 to 0.73)</p> <p>Thymoglobulin HR 0.77 (0.56 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall Chronic GvHD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR was 0.53 (95% CI 0.45 to 0.61; P&lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR=0.43 (95% CI 0.40 to 0.69; P&lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR=0.54 (95% CI 0.44 to 0.66; P&lt;0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 0.42 (95% CI 0.31 to 0.56)</p> <p>Thymoglobulin HR 0.70 (0.48 to 1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse</p> <p>Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.21 (95% CI 0.99 to 1.49; P = 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.14 (95% CI 0.90 to 1.45; P=0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 1.21 (95% CI 0.89 to 1.64)</p> <p>Thymoglobulin HR 0.92 (0.68 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non relapse mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.86 (95% CI 0.67 to 1.11; P = 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.91(95% CI 0.74 to1.13; P=0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.79 (95% CI 0.55 to 1.14; P=0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not available</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT‐ randomised controlled trial, RR Risk ratio, HR Hazard ratio, ATLG Anti‐ T cell Lymphocyte globulin, CI Confidence interval, </p> </div> </div> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009159-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009159-sec-0098"></div> <p>Immunosuppressive agents used as graft‐versus‐host disease (GVHD) prophylaxis impair the functioning of the donor‐derived immune cells thereby reducing the graft versus leukaemia effect and increasing the incidence of relapse. The available treatments for disease relapse vary according to the underlying disease and include a second allogeneic stem cell transplantation (SCT) after chemotherapy, tyrosine kinase inhibitors, epigenetic modulators with bcl‐2 inhibitors, donor lymphocyte infusions, etc (<a href="./references#CD009159-bbs2-0040" title="BarrettAJ , BattiwallaM . Relapse after allogeneic stem cell transplantation. Expert review of Haematology 2010 Aug;3:429-44.">Barrett  2010</a>). Success of these treatments is limited as relapse remains the biggest cause of mortality following an allogeneic SCT. After relapse‐related mortality it remains a significant cause of non‐relapse‐related morbidity and mortality (<a href="./references#CD009159-bbs2-0044" title="Flowers ME InamotoY , CarpenterPA , LeeSJ , KiemHP , PetersdorfEW , et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood2011;117(11):3214-9.">Flowers 2011</a>; <a href="./references#CD009159-bbs2-0034" title="Arai  S , Arora  M, Wang T , Spellman SR , He W, CourielDR ,  et al. Graft-versus-Host Disease Working Committee of the CIBMTR.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplant 2015 Feb;21:266-74. [DOI: 10.1016/j.bbmt.2014.10.021]">Arai 2015</a>; <a href="./references#CD009159-bbs2-0050" title="GreinixHT , EikemaDJ , KosterL , PenackO , Yakoub-AghaI , MontotoS , et al. Incidence of acute graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation over time: a study from the transplant complications and chronic malignancies working party of the EBMT. In: Blood. Vol. 132. 2018 Nov:Supplement 1.">Greinix 2018</a>; <a href="./references#CD009159-bbs2-0036" title="BachierCR , AggarwalSK , HenneganK , MilgroomA , FrancisK , DehipawalaS , et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: A US Claims Analysis. Transplantation and Cell Therapy  2021 Jun;27:504.e1-504.e6. [DOI: 10.1016/j.jtct.2020.12.027]">Bachier 2021</a>). Anti‐thymocyte globulin (ATG) has been used for the last two decades as a prophylactic tool to reduce the incidence of both acute and chronic GvHD.  </p> <section id="CD009159-sec-0099"> <h3 class="title" id="CD009159-sec-0099">Summary of main results</h3> <p>In this systematic review the role of anti‐thymocyte globulins (ATG) in GvHD prophylaxis was analysed. Ten randomised controlled trials (RCTs) evaluating the effect of ATG for GVHD prophylaxis in a total number of 1413 patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) was assessed. </p> <p>Our analysis (with or without meta‐analysis) led to the following main findings.</p> <p> <ol id="CD009159-list-0022"> <li> <p>The addition of ATG to standard treatment probably has little or no influence on the overall survival. </p> </li> <li> <p>ATG prophylaxis results in a large reduction in the incidence and severity of acute GVHD. </p> </li> <li> <p>Addition of ATG to standard GvHD prophylaxis results in a large reduction in the incidence and severity of chronic GVHD.  </p> </li> <li> <p>The incidence of relapse probably slightly increases with the addition of ATG to standard GVHD prophylaxis. </p> </li> <li> <p>The addition of ATG to standard treatment probably has little or no effect the incidence of non‐relapse‐related mortality. </p> </li> <li> <p>The incidence of graft failure was low in all studies. ATG prophylaxis may result in no increase in graft failure. </p> </li> <li> <p>Data on adverse events, quality of life and infections of ATG administration were heterogenous and hence not directly comparable. These are provided in a descriptive manner. </p> </li> </ol> </p> <p>Certainty of evidence was considered to be high by default due to the exclusive inclusion of RCTs. Risk of bias was considered to be low or unclear in all the included studies.  The reasons for downgrading the evidence were serious imprecision for overall survival, incidence of relapse, non‐relapse mortality or very serious imprecision for graft failure.<br/>The serious heterogeneity of the data on adverse events led us to downgrade the evidence.  </p> <p>Our review shows that ATG intervention reduces the incidence and severity of acute and chronic GvHD, but probably slightly increases the incidence of relapse‐related mortality. Several new treatment options are now available for the treatment of steroid refractory GVHD. Extracorporeal photopheresis, mycophenolate mofetil are the standard second‐line treatment options in this setting (<a href="./references#CD009159-bbs2-0072" title="PenackO , MarchettiM , RuutuT , AljurfM , BacigalupoA , BonifaziF , et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.. Lancet Haematology 2020 Feb;7:e157-e167. [DOI: 10.1016/S2352-3026(19)30256-X]">Penack 2020</a>). Recently a variety of kinase inhibitors such as Janus kinase inhibitors, Bruton's tyrosine kinase inhibitors, rho associated coiled‐coil protein kinases, etc have been approved and a variety are being investigated for the treatment of steroid refractory GVHD (<a href="./references#CD009159-bbs2-0041" title="BraunLM , ZeiserR . Kinase Inhibition as Treatment for Acute and Chronic Graft- Versus-Host Disease. Frontiers in Immunology 2021 November;12:760199. [DOI: 10.3389/fimmu.2021.760199.]">Braun 2021</a>). These agents have changed the scene such that more successful treatment options are available for this condition currently, thereby limiting the GVHD‐associated morbidity and mortality. </p> <p>Studies which provide long‐term follow‐up results could help in deciphering the role of ATG in survival, relapse as well as mortality. We cannot comment on the effects seen in the subgroup analysis. The certainty of our evidence is moderate to high and hence relevant in the decision‐making for this treatment group. The advent of alternative therapeutic options for GVHD and the use of haploidentical SCT upfront may change the need for an upfront GVHD prophylaxis with ATG. Some of the studies were conducted a decade ago questioning the feasibility of the results that may have changed alone with the advent of new and improved supportive therapies within this time frame. The newer studies have but confirmed the results in the current day and age hence highlighting the certainty of our data. </p> </section> <section id="CD009159-sec-0100"> <h3 class="title" id="CD009159-sec-0100">Overall completeness and applicability of evidence</h3> <p>This systematic review demonstrates a significant reduction in the incidence and severity of acute and chronic GvHD for patients following an allogeneic SCT provided they receive ATG as GVHD prophylaxis. Despite the fact that an improvement in OS could not be found this data supports a possible improvement in the morbidity and mortality resulting from GVHD and its treatment. As a result the patients may profit from this intervention. Disease relapse still remains the first and foremost cause of death after an allogeneic SCT. Hence, caution needs to be observed before considering ATG as an option for GVHD prophylaxis in patients with a high risk of disease relapse. </p> <p>Some of the studies were conducted a decade ago questioning the feasibility of the results that may have changed alone with the advent of new and improved supportive therapies within this time frame. The newer studies have but confirmed the results in the current day and age hence highlighting the certainty of our data and implying minimal change even with the availability of data. </p> <p>The results of the meta‐analysis should not be interpreted without considering the impact of the following factors. </p> <p> <ul id="CD009159-list-0023"> <li> <p>Anti‐thymocyte globulins are a heterogeneous group of polyclonal antibodies. Though all included studies used only rabbit ATG different types and doses of rabbit ATG were administered on different days. </p> </li> <li> <p>The studies analysed have a time gap of more than a decade between them. The three studies from the previous review (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>). Seven studies from the current update (<a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) might have been conducted under different standards of care. Supportive care and medical treatment have changed considerably in this time frame and thus influence the outcomes. </p> </li> <li> <p>Donors were HLA‐identical siblings in four studies (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a>) whereas matched unrelated donors were included in six studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>; <a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). In two studies one allele mismatch was allowed (<a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). </p> </li> <li> <p>Peripheral blood stem cells were the predominant graft source. In one study patients received both peripheral blood and bone marrow as the source of the graft (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>). </p> </li> <li> <p>The statistical consideration of competing risks has not been taken into account in the same manner in the analysis of outcomes in the different studies. </p> </li> <li> <p>The conditioning regimen was myeloablative in most studies. In two trials non myeloablative and reduced intensity conditioning regimens were also used (<a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>; <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>). </p> </li> <li> <p>Study populations were not homogeneous and patients suffered from different haematological diseases in different stages. </p> </li> <li> <p>The ten included studies, comprising 1413 participants, may not be adequately powered to detect small differences, especially in outcomes with few events such as graft failure. </p> </li> <li> <p>Lack of data on adverse events, quality of life and consistent data on infections made analysis of these parameters difficult. </p> </li> <li> <p>Long term follow‐up on these trials will help understand the impact of this intervention better. </p> </li> <li> <p>The data that we observed in the subgroup analysis need to be looked in larger cohorts to understand the relevance of the changes we observed. </p> </li> </ul> </p> </section> <section id="CD009159-sec-0101"> <h3 class="title" id="CD009159-sec-0101">Quality of the evidence</h3> <p>GRADE certainty of evidence was considered to be moderate for overall survival (<a href="./references#CD009159-fig-0003" title="">Analysis 1.1</a>), high for acute GVHD II‐IV (<a href="./references#CD009159-fig-0011" title="">Analysis 2.1</a>) and overall chronic GVHD (<a href="./references#CD009159-fig-0017" title="">Analysis 3.1</a>), moderate for incidence of relapse (<a href="./references#CD009159-fig-0024" title="">Analysis 4.1</a>) and NRM (<a href="./references#CD009159-fig-0029" title="">Analysis 5.1</a>), low for graft failure (<a href="./references#CD009159-fig-0037" title="">Analysis 6.1</a>) and moderate for adverse events (no meta‐analysis conducted).<br/>For the outcomes of overall survival (<a href="./references#CD009159-fig-0003" title="">Analysis 1.1</a>), incidence of relapse (<a href="./references#CD009159-fig-0024" title="">Analysis 4.1</a>), NRM (<a href="./references#CD009159-fig-0029" title="">Analysis 5.1</a>) the certainty was downgraded one point due to serious imprecision (small number of events and a confidence interval including both, potential benefit and harm). We downgraded two points for very serious imprecision for the outcome graft failure (<a href="./references#CD009159-fig-0037" title="">Analysis 6.1</a>), as altogether only 13 events occurred. <br/>For adverse events' no meta‐analysis was conducted, due to the inconsistencies in the reporting of the outcome. In the narrative synthesis we downgraded the level of evidence due serious imprecision, due to conflicting results in the available studies. Overall the quality of our evidence is moderate to high implying that the results are reliable and unlikely to change on availability of more data. The main factor which affected our certainty of evidence was the serious imprecision. </p> </section> <section id="CD009159-sec-0102"> <h3 class="title" id="CD009159-sec-0102">Potential biases in the review process</h3> <p>Different registries were reviewed to identify the potential studies. To account for potential biases arising in the preparation of this review, important steps in the review were performed independently by two review authors. Language restrictions were not applied in performing a comprehensive search. All studies included in the review were randomised controlled trials. </p> <p>The criteria defined for undertaking a sensitivity analysis were not different amongst the included trials except for the size of the trial. All trials were at least partly funded by pharmaceutical companies and only full text publications presenting mature results were included. See <a href="#CD009159-tbl-0014">Table 13</a> for details. </p> </section> <section id="CD009159-sec-0103"> <h3 class="title" id="CD009159-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>3 other groups have conducted systematic reviews on the impact of ATG as GVHD prophylaxis in an allogeneic SCT in recent years (<a href="./references#CD009159-bbs2-0035" title="AraiY , JoT , MatsuiH , KondoT , Takaori-KondoA . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukaemia and Lymphoma2017;58(8):1840-8.">Arai 2017</a>; <a href="./references#CD009159-bbs2-0057" title="KumarA , ReljicT , HamadaniM , MohtyM , Kharfan-DabajaMA . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplantation2019;54(7):1094-106.">Kumar 2019</a>; <a href="./references#CD009159-bbs2-0046" title="GagelmannN , AyukF , WolschkeC , KrogerN . Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biology of Blood &amp; Marrow Transplantation2017;23(12):2184-91.">Gagelmann 2017</a>). <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a> conducted a randomised controlled trial for the use of ATG as GVHD prophylaxis, but all patients (n = 170) received ATG in the study. The randomisation was done seven days post transplant based on a risk score and the intervention arm was then given two or three doses of ATG. As patients in both arms received ATG, one of our exclusion criteria, this study was not included in this review. The time of intervention with ATG was also post transplant in contrast to all the other studies in this review. The three other reviews (<a href="./references#CD009159-bbs2-0035" title="AraiY , JoT , MatsuiH , KondoT , Takaori-KondoA . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukaemia and Lymphoma2017;58(8):1840-8.">Arai 2017</a>; <a href="./references#CD009159-bbs2-0057" title="KumarA , ReljicT , HamadaniM , MohtyM , Kharfan-DabajaMA . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplantation2019;54(7):1094-106.">Kumar 2019</a>; <a href="./references#CD009159-bbs2-0046" title="GagelmannN , AyukF , WolschkeC , KrogerN . Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biology of Blood &amp; Marrow Transplantation2017;23(12):2184-91.">Gagelmann 2017</a>) included this study in their analysis. The differences in the trials included in the reviews was mainly due to the different time points when the search and meta‐analysis was conducted the other reviewers have a different subset of RCT which were analysed. </p> <p>The reviews by Arai and Kumar (<a href="./references#CD009159-bbs2-0035" title="AraiY , JoT , MatsuiH , KondoT , Takaori-KondoA . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukaemia and Lymphoma2017;58(8):1840-8.">Arai 2017</a>; <a href="./references#CD009159-bbs2-0057" title="KumarA , ReljicT , HamadaniM , MohtyM , Kharfan-DabajaMA . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplantation2019;54(7):1094-106.">Kumar 2019</a>) are congruous with our results and demonstrate a reduction in acute and chronic GVHD without influencing the OS or non relapse mortality. The comparison of two of the reviews with our update is shown <a href="#CD009159-tbl-0014">Table 13</a>. The review by <a href="./references#CD009159-bbs2-0046" title="GagelmannN , AyukF , WolschkeC , KrogerN . Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biology of Blood &amp; Marrow Transplantation2017;23(12):2184-91.">Gagelmann 2017</a> provided a comparison of the two ATG subtypes, Thymoglobulin and ATG‐F for all endpoints. Both ATG‐F and Thymoglobulin groups demonstrated a reduction in the incidence of acute GVHD Grade II‐IV and III‐IV as well as chronic GVHD. The authors conclude that ATG‐F is a better option than Thymoglobulin to prevent acute and chronic GvHD. Both preparations showed a similar TRM and thymoglobulin showed a slight benefit over ATG‐F in OS and relapse. In our subgroup analysis no differences could be identified between the different ATG types and donor status. For the doses administered subgroup analysis the chronic GVHD and incidence of relapse outcome showed a subgroup difference between the high and low dose thymoglobulin (<a href="./references#CD009159-fig-0019" title="">Analysis 3.3</a>; <a href="./references#CD009159-fig-0027" title="">Analysis 4.4</a>). The results point towards a benefit with the lower dose of ATG‐F. This is likely caused by the study by <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> which favours the control. Upon removal of the article <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> in a sensitivity analysis, all the observed heterogeneity is removed as well (I<sup>2</sup> = 0 %) and the group difference is no longer present. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009159-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD009159-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD009159-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 1: Overall survival (time to event)" data-id="CD009159-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 1: Overall survival (time to event)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 2: Overall survival at 1 year (binary)" data-id="CD009159-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 2: Overall survival at 1 year (binary)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 3: Overall survival at 2 years (binary)" data-id="CD009159-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 3: Overall survival at 2 years (binary)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 4: Overall survival at 3 years (binary)" data-id="CD009159-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 4: Overall survival at 3 years (binary)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 5: Overall survival (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin)" data-id="CD009159-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 5: Overall survival (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 6: Overall survival (time to event) ‐ subgroup analysis (ATG‐F low vs high dose)" data-id="CD009159-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 6: Overall survival (time to event) ‐ subgroup analysis (ATG‐F low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 7: Overall survival (time to event) ‐ subgroup analysis (Thymoglobulin low vs high dose)" data-id="CD009159-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 7: Overall survival (time to event) ‐ subgroup analysis (Thymoglobulin low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Overall survival, Outcome 8: Overall survival (time to event) ‐ subgroup analysis (Sibling donors vs MUDs)" data-id="CD009159-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Overall survival, Outcome 8: Overall survival (time to event) ‐ subgroup analysis (Sibling donors vs MUDs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 1: Acute GVHD II to IV" data-id="CD009159-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 1: Acute GVHD II to IV</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 2: Acute GVHD II to IV ‐ subgroup analysis (ATG‐F vs Thymoglobulin)" data-id="CD009159-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 2: Acute GVHD II to IV ‐ subgroup analysis (ATG‐F vs Thymoglobulin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 3: Acute GVHD II to IV ‐ subgroup analysis (ATG‐F low vs high dose)" data-id="CD009159-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 3: Acute GVHD II to IV ‐ subgroup analysis (ATG‐F low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 4: Acute GVHD II to IV ‐ subgroup analysis (Thymoglobulin low vs high dose)" data-id="CD009159-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 4: Acute GVHD II to IV ‐ subgroup analysis (Thymoglobulin low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 5: Acute GVHD II to IV ‐ subgroup analysis (Sibling donors vs MUDs)" data-id="CD009159-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 5: Acute GVHD II to IV ‐ subgroup analysis (Sibling donors vs MUDs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Acute GVHD, Outcome 6: Acute GVHD III to IV" data-id="CD009159-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Acute GVHD, Outcome 6: Acute GVHD III to IV</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 1: Overall chronic GVHD" data-id="CD009159-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 1: Overall chronic GVHD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 2: Overall chronic GVHD ‐ subgroup analysis (ATG‐F vs Thymoglobulin)" data-id="CD009159-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 2: Overall chronic GVHD ‐ subgroup analysis (ATG‐F vs Thymoglobulin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 3: Overall chronic GVHD ‐ subgroup analysis (ATG‐F low vs high dose)" data-id="CD009159-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 3: Overall chronic GVHD ‐ subgroup analysis (ATG‐F low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 4: Overall chronic GVHD ‐ subgroup analysis (Thymoglobulin low vs high dose)" data-id="CD009159-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 4: Overall chronic GVHD ‐ subgroup analysis (Thymoglobulin low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 5: Overall chronic GVHD ‐ subgroup analysis (Sibling donors vs MUDs)" data-id="CD009159-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 5: Overall chronic GVHD ‐ subgroup analysis (Sibling donors vs MUDs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 6: Limited chronic GVHD" data-id="CD009159-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 6: Limited chronic GVHD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic GVHD, Outcome 7: Extensive chronic GVHD" data-id="CD009159-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Chronic GVHD, Outcome 7: Extensive chronic GVHD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of relapse, Outcome 1: Incidence of relapse" data-id="CD009159-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Incidence of relapse, Outcome 1: Incidence of relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of relapse, Outcome 2: Incidence of relapse ‐ subgroup analysis (ATG‐F vs Thymoglobulin)" data-id="CD009159-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Incidence of relapse, Outcome 2: Incidence of relapse ‐ subgroup analysis (ATG‐F vs Thymoglobulin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of relapse, Outcome 3: Incidence of relapse ‐ subgroup analysis (ATG‐F low vs high dose)" data-id="CD009159-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Incidence of relapse, Outcome 3: Incidence of relapse ‐ subgroup analysis (ATG‐F low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of relapse, Outcome 4: Incidence of relapse ‐ subgroup analysis (Thymoglobulin low vs high dose)" data-id="CD009159-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Incidence of relapse, Outcome 4: Incidence of relapse ‐ subgroup analysis (Thymoglobulin low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Incidence of relapse, Outcome 5: Incidence of relapse ‐ subgroup analysis (Sibling donors vs MUDs)" data-id="CD009159-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Incidence of relapse, Outcome 5: Incidence of relapse ‐ subgroup analysis (Sibling donors vs MUDs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 1: Non‐relapse mortality (time to event)" data-id="CD009159-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 1: Non‐relapse mortality (time to event)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 2: Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin)" data-id="CD009159-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 2: Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 3: Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F low vs high dose)" data-id="CD009159-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 3: Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 4: Non‐relapse mortality (time to event) ‐ subgroup analysis (Thymglobulin low vs high dose)" data-id="CD009159-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 4: Non‐relapse mortality (time to event) ‐ subgroup analysis (Thymglobulin low vs high dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 5: Non‐relapse mortality (time to event) ‐ subgroup analysis (Sibling donors vs MUDs)" data-id="CD009159-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 5: Non‐relapse mortality (time to event) ‐ subgroup analysis (Sibling donors vs MUDs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 6: Non‐relapse mortality (binary)" data-id="CD009159-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 6: Non‐relapse mortality (binary)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 7: Non‐relapse mortality regarding GVHD" data-id="CD009159-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 7: Non‐relapse mortality regarding GVHD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Non‐relapse mortality, Outcome 8: Non‐relapse mortality regarding infections" data-id="CD009159-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Non‐relapse mortality, Outcome 8: Non‐relapse mortality regarding infections</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009159-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/urn:x-wiley:14651858:media:CD009159:CD009159-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Graft failure, Outcome 1: Graft failure" data-id="CD009159-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_t/tCD009159-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Graft failure, Outcome 1: Graft failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/media/CDSR/CD009159/image_n/nCD009159-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009159-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients after allogeneic stem cell or bone marrow transplantation<br/><b>Intervention:</b> ATG </p> <p><b>Control Intervention</b>: No ATG </p> <p><b>Setting</b>: inpatient </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No ATG</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ATG (95%CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Overall survival</b> (at 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low survival**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>HR 0.93 </b><br/>(0.77 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>1249<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/>(385 to 522) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High survival **</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>737 per 1000</b><br/>(690 to 777) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute GVHD II to IV </b><br/>(90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/>(251 to 331) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b><br/>(0.60 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1413<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall Chronic GVHD </b><br/>(up to 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>506 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/>(228 to 309) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/>(0.45 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1273<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small study (Study weight &lt;5%) by <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a><i> </i>was removed due to hetero‐geneity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of relapse</b> </p> <p>(up to 36 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(197 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21 </b><br/>(0.99 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1315<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Non‐relapse mortality</b> (at 36 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low ***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.67 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1370</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>110 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1000</b> (75 to 121) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High ***</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>449 per 1000</b> </p> <p>(371 to 537)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft failure</b> (during study) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> <p>(4 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.55</b> </p> <p>(0.54 to 4.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1240</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse Events</b> (during study) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>3 Studies reported no differences in AE between groups.</p> <p>1 study found similar SAEs between groups</p> <p>1 study reported a much higher incidence of AEs and SAEs in the ATG group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>543 <br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A narrative summary approach was chosen due to differences in reporting and the data could not be analysed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> represents the mean baseline risk from the studies in the meta‐analysis. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>** /*** For time‐to event analyses we used the lowest and highest observed values in the included studies to calculate ranges for the illustrative comparative risks. These illustrate the discrepancies in risk for varying populations.<br/>** Lowest observed by <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; highest observed by <a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>. </p> <p>*** Lowest observed by <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; highest observed by <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one point due to serious imprecision and 95% confidence interval including both potential benefit and harm.<br/><sup>2</sup> Downgraded two points due to very serious imprecision and 95% confidence interval including both potential benefit and harm.<br/><sup>3</sup> Downgraded one point due to serious heterogeneity in the reporting of adverse events between the studies, which limited comparability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ATG for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used ATG preparations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ATG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Manufacturer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Host animal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immunised with</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATGAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacia Upjohn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Horse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fresenius</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rabbit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Jurkat cell line</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lymphoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genzyme, formerly Mérieux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Horse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genzyme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rabbit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Human Thymocytes</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used ATG preparations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study design /</b> </p> <p><b>Study</b> </p> <p><b>dates</b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sample size (ATG/</b> </p> <p><b>Control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> <p><b>ATG/ Control</b> </p> <p><b>Median (range)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sex<br/>ATG(M/F):</b> </p> <p><b>Control (M/F)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Donor; <br/>HLA match;</b> </p> <p><b>Stem cell source; Conditioning;</b> </p> <p><b>Immuno‐suppression</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention ATG; Dose; Days of administration</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported Outcomes</b> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median duration of follow‐up<br/>ATG/ control</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Declaration of interest /</b> </p> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec. 1995 ‐ Dec. 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54(29/25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28(18‐48)/ <br/>29 (13‐51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Full match (6/6)</p> <p>BM;</p> <p>Cy/ TBI;</p> <p>CsA/Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin; 7,5mg/kg; ‐4, ‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Acute GVHD </p> <p><b>Secondary:</b> Overall survival, chronic GVHD, non‐relapse mortality, incidence of relapse, engraftment, event‐free survival. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34 years/ 2.85 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided /</p> <p>Government and Private sector funding (Sangstat)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec. 1995 ‐ Dec. 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 (27/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (14‐52)/</p> <p>28 (14‐46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Full match (6/6);</p> <p>BM; <br/>Cy/ TBI; </p> <p>CsA/Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>15mg/kg;</p> <p>‐5, ‐4,‐3,‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Acute GVHD </p> <p><b>Secondary:</b>Overall survival, chronic GVHD, non‐relapse mortality, incidence of relapse, engraftment, event‐free survival. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 years/</p> <p>1.47 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided /</p> <p>Government and Private sector funding (Sangstat)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Nov.2013 ‐ April 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263(132/131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (40‐61)/<br/>46 (40‐58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(76/56): (75/56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB;</p> <p>Full match;</p> <p>ATG</p> <p>PB 76: BM 6: PB+BM50, Control</p> <p>PB 77: BM 3:</p> <p>PB+BM 51;</p> <p>CyTBI, BuCY, FluBU;</p> <p>CsA+ Mtx +MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>4.5mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> grade 2‐4 aGVHD on day 100. </p> <p><b>Secondary:</b> Engraftment, chronic GvHD 2 years, Immune‐suppressant free at 2 years and 3 years ‐non‐relapse mortality, GvHD related Non relapse mortality, cumulative incidence of relapse, overall survival, leukaemia free survival as well as graft versus host disease relapse free survival, Infections </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,163 days (range 182‐2027 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /</p> <p>Governmental funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>April 2017 ‐Jan. 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120(60/60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.5(18‐64)/</p> <p>47.5(20‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(23/37):(36/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB; Fully matched(4/4)ATG (35): Control (39), Major mismatch ATG (12): control (8), Minor mismatch ATG (6): Control (7), major and minor mismatch ATG (7), Control (6); </p> <p>PB; BuCy or CyTBI or FluBU or FluBuTBI; CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin 2.5mg/kg; 1.25mg/kg/day on days ‐3 and ‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> GVHD at 2 years </p> <p><b>Secondary:</b> Engraftment; Immune reconstitution; Cumulative incidences of acute GVHD; Infectious complications relapse (CIR); non relapse mortality and disease free survival; overall survival; a composite end point of chronic GVHD free and relapse free survival; Recipient reported outcomes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /<br/>Not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Aug. 2015 ‐ Dec. 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72(42/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6(38‐62)/</p> <p>45.6(36‐63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(24/18): (18/12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB; Fully matched (6/6) ATG (25): control (17). Major mismatch ATG(7):control (8)Minor mismatch ATG (8): control (5), Bidirectional mismatch ATG (2): control(0) </p> <p>PB;</p> <p>BuCy or CyTBI or FluBu; CsA+ Mtx+MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin; 5mg/kg; 1,5mg/kg on day‐5 and 3.5mg/kg on day ‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Incidence of chronic GVHD at 2 years </p> <p><b>Secondary:</b> Non‐relapsed mortality; relapse GVHD‐free; relapse free survival; incidence of a GvHD; engraftment, DFS; OS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>874 days or 29 months</p> <p>(962 days for patients alive, 391 days for patients died)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, No conflicts of interests present /</p> <p>Governmental funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>May 2003 ‐ Feb. 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201(103/98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (18‐60)/</p> <p>39 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(58/45): (58/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>35 HLA ‐ C mismatched</p> <p>All others fully matched (8/8)</p> <p>ATG</p> <p>PB:BM 82:21, control</p> <p>PB:BM 82:16; <br/>CyTBI or BuCy; </p> <p>CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F; 60mg/kg; ‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> severe aGvHD grade III‐IV or death </p> <p><b>Secondary:</b> Overall survival, acute GVHD, chronic GVHD, non‐relapse mortality, adverse effects, disease‐free survival, incidence of relapse, engraftment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05 years/1.81 years Update 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Lecture fees from Fresenius Biotech GmbH) /</p> <p>Private sector funding (Fresenius Biotech GmbH)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Dec.2006 ‐ Feb. 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155(83/72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18‐64)/</p> <p>43.5 (21 ‐ 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(53/30): (40/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB;</p> <p>Full match;</p> <p>PB; BuCy +/‐ Etoposide;</p> <p>CsA+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>30mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> 2‐year cumulative<br/>incidence of chronic GVHD </p> <p><b>Secondary:</b> Cumulative incidence of chronic GVHD at 2 years, incidences of engraftment, acute GVHD, nonrelapse‐related death, relapse‐free and overall survival at 2 years, and a composite end point of chronic GVHD–free and relapse‐free survival at 2 years, Infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Lecture fees (Neovii Biotech) /</p> <p>Medical associations and Private sector funding (Neovii Biotech)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Oct. 2011 ‐ Oct. 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (126/128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (18‐64)/</p> <p>49 (19‐65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(60/66): (79/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>Allele‐level matched at HLA‐A, ‐B, ‐C, and ‐DRB1;</p> <p>ATG</p> <p>PB:BM:NK</p> <p>95: 22:9, Control</p> <p>PB:BM:NK</p> <p>101:27:0;</p> <p>CyTBI, BuCy, FluBU;</p> <p>Tac+Mtx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>20mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Moderate‐severe cGVHD‐free survival </p> <p><b>Secondary:</b> overall survival (OS), progression‐free survival (PFS), moderate‐severe cGVHD‐free and relapse‐free survival (cGRFS), cumulative incidence of relapse and nonrelapse mortality (NRM), acute GVHD, and engraftment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported, Consulting fees and honoraria /</p> <p>Individual funding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>June 2010 ‐ July 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196 (99/97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐57)/</p> <p>49 (40‐56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(63/36): (65/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>ATG: 83 Full match, 16 one allele mismatch</p> <p>Control:</p> <p>79 Full match, 18 one allele mismatch;</p> <p>ATG</p> <p>PB:BM 88:11, control PB:BM 85:12;</p> <p>Myelo and non‐myeloablativ;</p> <p>CsA orTac and</p> <p>Mtx or MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin;</p> <p>4,5mg/kg;</p> <p>‐3,‐2,‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Freedom from systemic immunosuppressive drugs without resumption up to 12 months after transplantation<br/><b>Secondary:</b> time to neutrophil and platelet engraftment (analysed only for patients undergoing myeloablative conditioning); the incidence of AGVHD; the incidence of and time to CGVHD; times to non‐relapse mortality, all‐cause mortality, and relapse of haematological malignancy; event‐free survival; graft rejection or failure (yes vs no); incidence of serious infection and cytomegalovirus reactivation; doses of immunosuppressive therapy at 12 months; and recipient‐reported outcomes (quality of life) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Membership on advisory board (Sanofi) /</p> <p>Government and Private sector funding (Sanofi)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel group,<br/>Randomised controlled trial </p> <p>Date not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (19/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4‐42)/</p> <p>(12‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUD;</p> <p>ATG 14 fully matched 5 mismatched/ Control 18 fully matched 6 mismatched;</p> <p>NR; FluBuCy;</p> <p>CsA+ MMF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F;</p> <p>37.5mg/kg;</p> <p>‐5, ‐4,‐3,‐2,‐1,0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute GVHD, chronic GVHD, quality of life.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 days (150‐490)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported /</p> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>SIB: Sibling, MUD: Matched unrelated donor, PB: Peripheral blood, BM: Bone marrow, NK: Not known, BuCy: Busulfan Cyclophosphamide, CyTBI: Cyclophosphamide Total body irradiation, FluBu: Fludarabine Busulfan, CsA: Cyclosporin A, Tac: Tacrolimus, MMF: Mycophenolate Mofetil, Mtx: Methotrexate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ATG used in intervention arm</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of ATG</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dosage</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (Sangstat, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.75mg/kg on days ‐4, ‐3 (total dose 7.5 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (Sangstat, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.75mg/kg on days ‐5, ‐4, ‐3, ‐2 (total dose 15mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐10mg/kg on days ‐4,‐3,‐2,‐1 and 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG‐F (Fresenius, rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20mg/kg on days ‐3, ‐2, ‐1 before transplantation (total dose 60 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG [formerly termed ATG‐Fresenius] (Fresenius, Neovii Biotech)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10mg/kg/day on days ‐3,‐2, ‐1,</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐Sanofi, (rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG [formerly termed ATG‐Fresenius] (Neovii Biotech)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg/day on days ‐3,‐2, ‐1,</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐Sanofi, (rabbit ATG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4,5mg/kg divided over day ‐3, ‐2,‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin (rabbit ATG, Sanofi, Paris, France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5mg/kg (1,5mg/kg day ‐5 and 3.5mg/kg day ‐4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thymoglobulin, Genzyme‐ Sanofi, Cambridge MA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5mg/kg: 1.25mg/kg/day on days ‐3 and ‐2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>[Day 0 is day of transplant]</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ATG used in intervention arm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Standard GVHD Prophylaxis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cyclosporine (CsA)/ Tacrolimus (Tac)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methotrexate</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mycophenolate Mofetil (MMF)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA 2mg/kg from day ‐1 to +20, then 6 to 10 mg/kg per day for at least 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m² on day +1,</p> <p>10 mg/m² on days +3,+6 and +11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with a plasma concentration of 150‐300ng/ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1, </p> <p>10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA Target concentration 200 ng/mL, tapered after day 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m² day 1,</p> <p>10 mg/m² days +3, +6, +11.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1 and </p> <p>10 mg/m<sup>2</sup> on days +3, +6, and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA or Tac administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Administered, but dosage not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Administered, but dosage not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tac (with a target serum trough level of 5 to 15 ng/mL) and IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m2 on day +1, 10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 mg/kg CsA continuous intravenous drip, started on day 21, changed to orally when GI function recovered with a dose of 5 mg/kg administered as 2 divided doses, and CsA trough concentration maintained at 200‐ 300 ng/mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1 and 10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 g MMF twice a day, starting on day +21 and continuing to day +30 for 1 month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with concentration 150‐ 250 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 mg/m<sup>2</sup> on day +1, </p> <p>10 mg/m<sup>2</sup> on days +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5g twice daily from days ‐10 to +14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CsA with concentration 150‐300ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10mg/m<sup>2</sup> on days +1, +3, +6 and +11. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not administered</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Day 0 is day of transplant.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Standard GVHD Prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Conditioning therapy</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conditioning regimen</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TBI [centre specific: 12 Gy (2 Gy twice a day for 3 days), 9 Gy (3.3 Gy for 3 days), 13.2 Gy (120 cGy for 11 days) and (10 Gy single dose)]plus Cy (dosage not reported), N = 54 (100%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fludarabine 25 mg / m<sup>2</sup> (day‐8 to ‐4), Bu 3 mg/kg (day ‐8 to ‐5) and cyclophosphamide 60 mg / kg (day‐4 to‐3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TBI (8‐12 Gy) plus Cy (2 doses of 60 mg / kg): N = 102 (50.5 %), Busulfan (14 to 16 mg/kg orally) plus Cyclophosphamide (2x60 mg / kg): N = 52 (25.7 %), other myeloablative regimens: N = 47 (23.3 %) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cy (120 mg/kg) and TBI (12 Gy) or Bu (16 mg/kg orally or 12.8 mg/kg IV), with or without etoposide (30 to 60 mg/kg) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myeloablative or non‐myeloablative and reduced‐intensity conditioning regimens.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CyTBI:Cy (120 mg/kg total intravenously (IV)) and fractionated TBI (12 Gy); BuCy: Bu 16 mg/kg orally or 12.8 mg/kg IV and Cy 120 mg/kg IV; BuFlu, Busulfan 16 mg/kg orally or 12.8 mg/kg IV and fludarabine 120 mg/m<sup>2</sup> IV. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BuCy, TBI and FluCy or FluBu</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BuCY, CyTBI and FluBU</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bu (12.8 mg / kg) Cy (120 mg / kg), Cy (120 mg/kg) TBI (1320 cGy of fractionated TBI) or Flu (150 mg/ m<sup>2</sup>) Bu (6.4 mg/ kg) or Flu (150 mg/m<sup>2</sup>)Bu (6.4 mg / kg) TBI (400 cGy of fractionated TBI) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Cy: Cyclophosphamide, Bu: Busulfan, Flu: Fludarabine, TBI: Total body irradiation, IV: intravenously </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Conditioning therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Patient characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median age</b> </p> <p><b>(range) ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median age</b> </p> <p><b>(range) control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Male(%) ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Male(%) Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Underlying disease ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Underlying disease Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Early‐stage disease</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Advanced‐stage disease</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (18‐48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (13‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:62%</p> <p>Control:60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:38%</p> <p>Control:40%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (14‐52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (14‐46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:22%</p> <p>Control:36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:78%</p> <p>Control:64%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (4‐42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (12‐51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:7</p> <p>AML:6</p> <p>ALL:3</p> <p>AA: 2</p> <p>Thalassaemia:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:8</p> <p>AML:10</p> <p>ALL:5</p> <p>NHL:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18‐60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: N = 37<br/>AML: N = 55<br/>CML: N = 6<br/>MDS: N = 5<br/>OMF: N = 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: N = 33<br/>AML: N = 46<br/>CML: 11<br/>MDS: N = 5<br/>OMF: N = 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:62 %</p> <p>Control:44 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:38 %</p> <p>Control:56 %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (18 ‐ 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (21‐ 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL: 55</p> <p>AML 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:55</p> <p>ALL:17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (40‐56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML: 7 (7 %)</p> <p>AML: 39 (39 %)</p> <p>ALL:13 (13 %)</p> <p>MDS:11 (11 %)</p> <p>CLL:8 (8 %)</p> <p>NHL:14 (14 %)</p> <p>Other:7 (7 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CML:5 (5 %)</p> <p>AML:39 (40 %)</p> <p>ALL:16 (17 %)</p> <p>MDS:12 (12 %)</p> <p>CLL:8 (8 %)</p> <p>NHL:13 (13 %)</p> <p>Other:4 (4 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:57 (58 %)</p> <p>Control:59 (61 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:34 (34 %)</p> <p>Control:N = 34 (35 %)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (18‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (19‐65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:24 (19 %)</p> <p>AML:83 (66 %)</p> <p>MDS:19 (15 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALL:34 (26.6 %)</p> <p>AML:80 (62.5 %)</p> <p>MDS:14 (10.9 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (40‐61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (40‐58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:88 (66.7 %)</p> <p>ALL:18 (13.6 %)</p> <p>CML:2 (1.5 %)</p> <p>MDS:24(18.2 %)</p> <p>NHL:0 (0 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:88 (67.2 %)</p> <p>ALL:16 (12.2 %)</p> <p>CML:1 (0.8 %)</p> <p>MDS:23 (17.6 %)</p> <p>NHL:3 (2.3 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6 (38‐62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.6 (36‐63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:21</p> <p>ALL:12</p> <p>MDS:9</p> <p>NHL:0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:14</p> <p>ALL:5</p> <p>MDS:9</p> <p>NHL:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (20‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (18‐64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:33 (55 %)</p> <p>ALL:27(45 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AML:33 (55 %)</p> <p>ALL:27(45 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk ATG (8): Control (9)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>* A follow‐up publication (<a href="./references#CD009159-bbs2-0038" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5.">Bacigalupo 2006</a>) reported pooled underlying disease of patients surviving day 100 of both studies (<a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a>; <a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a>): Intervention group: Acute Leukaemia: N = 11, CML: N = 27, MDS: N = 0; Control group: Acute Leukaemia: N = 11, CML: N = 25, MDS: N = 1. </p> <p>Abbreviations: SAA: Severe aplastic anaemia; AML: Acute myeloid leukaemia; ALL: Acute lymphoid leukaemia; CML: Chronic myeloid leukaemia; LLL: Leukaemic lymphoblastic lymphoma; MDS Myelodysplastic syndrome; OMF: Osteomyelofibrosis; NHL Non‐Hodgkin Lymphom; N‐not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Patient characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No: of patients</b> </p> <p><b>Total (ATG/</b> </p> <p><b>Control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> <p><b>ATG/ Control</b> </p> <p><b>Median (range)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex</b> <br/><b>ATG(M/F):</b> </p> <p><b>Control (M/F)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Donor; HLA match</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stem cell source</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conditioning;</b> </p> <p><b>Immunosuppression</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ATG; Dose; Days of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0030" title="JPRN-jRCTs031180435. A randomized trial of ATG in HLA 1-locus mismatched unrelated bone marrow transplantation. https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs0311804352019. ">JPRN‐jRCTs031180435</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 in total, estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age ≥ 16 and ≤ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Men and Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Related or Unrelated; Matched and mismatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 ‐ 0.03 mg/kg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Death, Relapse, </p> <p>Grades III‐IV acute GVHD,</p> <p>Severe chronic GVHD or mild chronic GVHD requiring systemic steroid treatment)</p> <p><b>Secondary:</b> Cumulative incidence of neutrophil engraftment, Cumulative incidence of platelet engraftment, Cumulative incidence of acute GVHD and severity, Cumulative incidence of chronic GVHD and severity, Cumulative incidence of relapse, Cumulative incidence of non‐relapse mortality, </p> <p>Probability of disease‐free survival, Probability of overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0031" title="JPRN-UMIN000028008. A randomized trial comparing conventional GVHD prophylaxis vs. anti-thymocyte globulin-combined GVHD prophylaxis in HLA 1-locus mismatched unrelated bone marrow transplantation. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000308402017. ">JPRN‐UMIN000028008</a> </p> <p>Parallel randomised controlled trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 in total, estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age ≥ 16 and ≤ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Men and Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unrelated; HLA 1‐locus mismatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 ‐ 0.03 mg/kg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> Success rate at 1 year after transplantation; Death; Relapse;<br/>Grades III‐IV acute GVHD; Severe chronic GVHD or mild chronic GVHD requiring systemic steroid treatment) </p> <p><b>Secondary:</b> Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0032" title="NCT04203108. ATG in HLA-matched sibling HSCT as GVHD prophylaxis. https://clinicaltrials.gov/show/NCT042031082019. ">NCT04203108</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimated n = 266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age of 18‐65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sibling; Matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary:</b> </p> <p>Incidence of cGVHD 2 years</p> <p><b>Secondary:</b> Overall survival 2 years; </p> <p>Disease‐free survival; 2 years,</p> <p>Incidence of aGVHD 100 days, 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Governmental funding</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of ongoing studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Chronic GVHD</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median follow‐up (rounded)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall chronic GHVD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Limited chronic GVHD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Extensive chronic GVHD</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 20 (40 %)<br/>Control: N = 13 of 20 (65 %), (P = 0.08) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 7 of 18 (39 %)<br/>Control: N = 10 of 17 (59 %), (P = 0.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG group 250 days(150‐440)</p> <p>Control group 440 days (300‐1095 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:35.5%</p> <p>Control:77.5%</p> <p>P=&lt;0.0000001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 27 of 90 (30 %)<br/>Control: N = 47 of 80 (59 %) </p> <p>(P &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 16 of 90 (18 %)<br/>Control: N = 13 of 80 (16 %), </p> <p>(P = NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 11 of 90 (12 %)<br/>Control: N = 34 of 80 (43 %), </p> <p>(P &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 22 (26.5 %)</p> <p>Control: 46 (63.9 %)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 17 (20.5 %)</p> <p>Control: 22 (30.6 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 5 (6 %)</p> <p>Control: 24 (33.3 %)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:22 % (15‐31)</p> <p>Control:33 % (24‐43)</p> <p>P=0.065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 13 % (13)<br/>Control 29 % (28) </p> <p>P=0.0083</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIH criteria</p> <p>ATG: 16 % (9.7‐24)</p> <p>Control: 38 % (29‐47)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIH criteria Moderate‐severe</p> <p>ATG: 12 % (6.7‐19)</p> <p>Control: 33 % (25‐42)</p> <p>P&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,163 days (range 182‐2027 days) post transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 27.9 % (27.6‐28.2)</p> <p>Control: 52.2 % (52.1‐52.9)</p> <p>P&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 8.5 (8.4‐8.6)<br/>Control: 23.2 (22.9‐23.5) </p> <p>P=0.029</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 months (874 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 37.5 %</p> <p>Control 52.5% p=&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 9.5 %</p> <p>Control 20 %</p> <p>P=0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 19.8 %</p> <p>Control 38.4 % p=0.060</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 25% Control 65.4% p=&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>* Results were extracted from long term follow‐up (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>): NR‐ Not reported, NIH National Institute of health </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Chronic GVHD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Incidence of relapse</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of</b> </p> <p><b>evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relapse</b> </p> <p><b>ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relapse</b> </p> <p><b>Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>HR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 /29 (10 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 /25 (12 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/27 (36 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 /28 (18 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34/103 (32.6 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 /98 (28.2 %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 32.2 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 25.5 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 11 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 32 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 21 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 20.8 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 15.4 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.362</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6/42) 23.1 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(10/30) 36.5 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.078</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 20 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNR 9.3 %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.055</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>* Results were extracted from long term follow‐up (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>): NR‐ not reported, NNR‐number not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Incidence of relapse</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Non‐relapse mortality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time of evaluation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall non‐relapse mortality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mortality from GVHD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mortality from Infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Non‐relapse mortality from other causes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:12/ 29 (42%) <br/>Control: 10/ 25 (40%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 29 (28%)<br/>Control: N = 8 of 25 (32%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 2/29 (7%)<br/>Control: 2/25 (8%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 2 of 29 (7%)<br/>Control: N = 0 of 25 (0%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other causes include: Multi‐organ failure.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 11/27 (41%)<br/>Control: 14/28 (50%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 3 of 27 (11%)<br/>Control: N = 11 of 28 (39%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 8 /27 (30%)<br/>Control: 2 /28 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 0 of 27 (0%)<br/>Control: N = 1 of 28 (4%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other causes include: Multi‐organ failure.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>440 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients died in the control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years post‐transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years post‐transplant:</p> <p>ATG: 20/ 103 (19.6%)<br/>Control:28/ 98 (28.9%), HR 0.68 (95% CI 0.38 to 1.22, P = 0.20) </p> <p>3 years post‐transplant:**</p> <p>ATG: 20 /103 (19%)<br/>Control: 33/98 (34%), HR = 0.68 (P = 0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 1 of 103 (1%)<br/>Control: N = 13 of 98 (13%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 8 of 103 (8%)<br/>Control: N = 7 of 98 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: N = 11 of 103 (11%)<br/>Control: N = 9 of 98 (9%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up for overall non‐relapse mortality is 2 and 3 years, for details it is 2 years. Other causes include: Graft failure, interstitial pneumonia, multi‐organ failure and other causes occurring less than once. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:14%</p> <p>Control:12%</p> <p>P=0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:23%</p> <p>Control:24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG.21%</p> <p>Control:13.5%</p> <p>P=0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:9.9%</p> <p>Control:14.3%</p> <p>P=0.552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG:3%</p> <p>Control:5.3%</p> <p>P=0.345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 6% 8/132</p> <p>Controls: 6.8% 9/131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 2.2%</p> <p>Control: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall 14%</p> <p>ATG:13%</p> <p>Control:8.5%</p> <p>P=0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients in ATG group and 1 in control died of respiratory failure. 1 patient in ATG group died of gastrointestinal haemorrhage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 10%</p> <p>Control 17.5%</p> <p>P=0.330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Numbers of patients with mortality from GVHD were obtained by personal communication with the authors. </p> <p>** 3‐year overall NRM was reported in a long‐term follow‐up publication (<a href="./references#CD009159-bbs2-0078" title="SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011 June;117(23):6375-82.">Socié 2011</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Non‐relapse mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0012"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Engraftment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of engraftment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Result ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Result control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary graft failure ATG group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary graft failure Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with neutrophil counts ≥ 0.5 x 10/L (%), time of evaluation not mentioned.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 of 29 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 of 25 (84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil count of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 18 (13 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 17 (13 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with neutrophil counts ≥ 0.5 x 10/L (%) time of evaluation not mentioned.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 of 29 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 of 28 (89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil count of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (13 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (14 to 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from transplantation (day 0) to the first day of achieving an absolute neutrophil count of ≥ 0·5 × 10/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12(8‐21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/19 (94.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/24 (95.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil counts of 0.5 x 10/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 24 (range 3 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 17 (range 10 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median days to reach neutrophil counts of 1.0 x 10^9/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 26 (range 3 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 19 (range 12 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Engraftment with neutrophils ≥ 1.0 × 10/L at day 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 of 103 (97.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 of 98 (94.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment≥0.5×10<sup>9</sup>/L) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18(10‐31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15(11‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet count of ≥ 20 × 10⁹/ L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20(10‐110)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(6‐29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from transplantation (day 0) to the first day of achieving an absolute neutrophil count of ≥ 0·5 × 10/L for three consecutive measurements on different days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (14‐22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (13‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from day 0 to the first day of achieving a platelet count of ≥ 20 × 10⁹/ L for three consecutive measurements on different days without needing platelet transfusions in the previous 7 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (13‐27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5 (12.5‐23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment was defined as the first of 3 consecutive days of absolute neutrophil count&gt;0.5x10<sup>9</sup>/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24(5‐45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19(8‐41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4% n= 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8% n=1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet engraftment was defined as the first of 3 consecutive days with self‐supported platelet counts &gt;20x 10<sup>9</sup>/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (6‐205)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19(5‐45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count &gt;0.5 x 10<sup>9</sup>/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (9‐24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(8‐23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet engraftment was defined as the first of 7 consecutive days with a platelet count &gt;20 x 10<sup>9</sup>/L without transfusion dependence. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (8‐68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil engraftment is day of achieving an absolute neutrophil count of ≥ 0·5 × 10<sup>9</sup>/L for three consecutive days. </p> <p>Platelet engraftment &gt;20x 10<sup>9</sup>/L for 7 consecutive days without transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12(8‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13(9‐32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil and platelet engraftment was defined as an absolute neutrophil count of &gt; 0.5 10<sup>9</sup>/L during the first of three consecutive days or a platelet count of &gt; 20x10<sup>9</sup>/L without transfusion support during the first of seven consecutive days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 12 (7–23)</p> <p>Platelet count: 14 (9–30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 12 (7–25)</p> <p>Platelet count: 12 (5–35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count: 0.902</p> <p>Platelet count: 0.414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>All patients engrafted in the studies by Finke (<a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a>) and Chang (<a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>). Walker (<a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a>) analysed engraftment only for 66 patients in both group who received myeloablative conditioning </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Engraftment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0013"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Infections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall incidence of Infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bacterial infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Viral infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fungal infections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Infection prophylaxis:</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0001" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall viral infections not reported,</p> <p>CMV reactivation rate:</p> <p>ATG: 83%; control 88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciprofloxacin, Fluconazole, high‐dose immunoglobulins, acyclovir (foscarnet instead in one of four centres) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0002" title="BacigalupoA , LamparelliT , BarisioneG , BruzziP , GuidiS , AlessandrinoPE , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation2006;12(5):560-5. BacigalupoA , LamparelliT , BruzziP , GuidiS , AlessandrinoPE , Di BartolomeoP , et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood2001;98(10):2942-7. ">Bacigalupo 2001b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall viral infections not reported,</p> <p>CMV reactivation rate:</p> <p>ATG: 67%; control 78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciprofloxacin, Fluconazole, high‐dose immunoglobulins, acyclovir (foscarnet instead in one centre) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0006" title="FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology2009;10(9):855-64. FinkeJ , BethgeWA , SchmoorC , OttingerHD , StelljesM , ZanderAR , et al. Supplement to: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised,open-label, multicentre phase 3 trial. Lancet Oncology published online August 19,2009. [DOI: DOI:10.1016/S1470-2045(09)70225-6]FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology2017;4(6):e293-e301. FinkeJ , SchmoorC , BethgeWA , OttingerH , StelljesM , VolinL , et al. Randomized trial on GVHD prophylaxis with or without anti-human t-lymphocyte immunoglobulin ATG-fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: Final long-term results after 8.6 years median follow-up. In: Blood. Vol. 126. 2015:853. FinkeJ , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biology of Blood &amp; Marrow Transplantation2012;18(11):1716-26. SociéG , SchmoorC , BethgeWA , OttingerHD , StelljesM , ZanderAR , et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. In: Blood. Vol. 117. 2011 June:6375-82. ">Finke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 104 of 106 (98%)<br/>Control: 92 of 95 (97%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 66 of 106 (62%)<br/>Control: 65 of 95 (68%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 79 of 106 (75%)<br/>Control: 61 of 95 (64%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 35 of 106 (33%)<br/>Control: 36 of 95 (38%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported, "Supportive care was done according to centre‐specific standards."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0007" title="BonifaziF , SolanoC , WolschkeC , SessaM , PatriarcaF , ZallioF , et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology2019;6(2):e89-e99. BonifaziF , SolanoC , WolschkeC , SessaM , PiniM , SelleriC , et al. Significant Improvement of QoL by using ATG as part of the conditioning regimen followed by HLAidentical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG Family Study). In: Bone Marrow Transplantation. Vol. 52. 2017:539-40. BonifaziF , SolanoC , WolschkeC , SessaM , ZallioF , SelleriC , et al. Prophylaxis with ATLG significantly improves chronic graft-versus-host disease / relapse-free survival and quality of life after a myeloablative hla identical sibling transplant for acute leukemia patients in complete remission. Long-term follow-up of the randomized atg familystudy. In: Blood. Vol. 130. 2017. KrogerN , SolanoC , WolschkeC , BandiniG , PatriarcaF , PiniM , et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. New England Journal of Medicine2016;374(1):43-53. SolanoC , BonifaziF , WolschkeC , PatriarcaF , PiniM , NaglerA , et al. Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy). Bone Marrow Transplantation2015;50:S1. ">Kroger 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 48 of 83 (58%)<br/>Control: 39 of 72 (54%) (P = 0.65). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary infection:<br/>ATG: 6 of 83 (7%)<br/>Control: 10 of 72 (14%) (p=0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation:<br/>ATG: 18/83 (22%)<br/>Control: 18/72(25%)<br/>P=0.63) </p> <p>EBV reactivation:<br/>ATG 3/83 (4%)<br/>Control: 1/72(1%) (p=0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 3/83 (4%)<br/>Control: 3/72 (4%)<br/>(p=0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0009" title="RoyJ , PanzarellaT , CoubanS , CoutureF , DevinsGM , ElemaryM , et al. Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: longer follow-up of a multicentre cell therapy transplant Canada randomized trial. In: Blood. Vol. 134 (Supplement 1). 2019:875. [DOI: https://doi.org/10.1182/blood-2019-123275]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology2020;7(2):e100‐e111. WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: follow up of a CBMTG randomized trial. In: Bone Marrow Transplantation. Vol. 53. 2019:395‐6. [DOI: https://doi.org/10.1038/s41409-018-0354-7]WalkerI , PanzarellaT , CoubanS , CoutureF , DevinsG , ElemaryM , et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology2016;17(2):164-713. WalkerI , SchultzKR , TozeCL , KerrHM , MooreJ , SzwajcerD , et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. In: Blood. Vol. 124. 2014. WalkerI . Correction: pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial(The Lancet Oncology (2016) 17(2) (164-173), (S1470204515004623) (10.1016/S1470-2045(15)00462-3)). Lancet Oncology2018. ">Walker 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any infection:<br/>ATG: 42/99 (42%)<br/>Control: 37/97 (38%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clostridium difficile:<br/>ATG: 2/99 (3%)<br/>Control: 3/97 (5%) </p> <p>Escherichia coli bacteria:<br/>ATG: 0/99 (%)<br/>Control: 2/97 (3%) </p> <p>Other bacteria:<br/>ATG: 11/99 (18%)<br/>Control: 20/97 (32%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epstein‐Barr virus:<br/>ATG: 20/99 (33%) Control: 2/97 (3%) </p> <p>Adenovirus:<br/>ATG: 2/99 (3%)<br/>Control: 2/97 (3%) </p> <p>CMV:<br/>ATG: 5/99 (8%)<br/>Control: 5/97 (8%) </p> <p>Other viruses:<br/>ATG: 6 /99 (10%)<br/>Control: 6 /97 (10%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fungal:<br/>ATG: 3/99 (5%)<br/>Control: 4/97 (7%) </p> <p>Protozoal<br/>ATG: 1/99 (2%)<br/>Control: 0/97 (0%)<br/>Multiple organisms:<br/>ATG: 3/99 (5%)<br/>Control: 4/97 (7%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSI at day 30:<br/>ATG: 4% (3.0 ‐ 4.6)<br/>Control: 3% (3.0 ‐ 3.2) (P=0.769) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation at day 100:<br/>ATG: 23% (22.4‐23.0)<br/>Control: 24% (23.6 ‐ 24.2) (P =0.674) </p> <p>EBV reactivation at day 180:<br/>ATG: 8% (7.7 ‐7.9) <br/>Control: 3% (3.3‐3.5) (P = 0.289) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFD at 1 year:<br/>ATG: 14% (13.5 ‐ 13.9) <br/>Control: 14% (13.6‐14.0) (P = 0.843) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 26 /42 (62%)<br/>Control: 21/30 of 72 (70%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV reactivation:<br/>ATG: 11/42 (26%)<br/>Control: 6/30(20%)<br/>P=0.587 </p> <p>EBV reactivation:<br/>ATG11/42 (26%)<br/>Control: 2/30(7%) (p=0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 4/42 (10%)<br/>Control: 13/30 (43%) </p> <p>P=0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG 10/60 (17%)</p> <p>Control 8/60(13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EBV reactivation ATG 22%: Control 5%, CMV disease ATG 5%: Control 12%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NR‐ Not reported, BSI‐ Bacterial super infections, IFD‐ Invasive fungal disease, CMV‐ cytomegalovirus, EBV‐ Epstein Barr virus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009159-tbl-0014"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Comparison of contemporary systematic review analyses</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>This review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009159-bbs2-0057" title="KumarA , ReljicT , HamadaniM , MohtyM , Kharfan-DabajaMA . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplantation2019;54(7):1094-106."><b>Kumar 2019</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009159-bbs2-0035" title="AraiY , JoT , MatsuiH , KondoT , Takaori-KondoA . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukaemia and Lymphoma2017;58(8):1840-8."><b>Arai 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009159-bbs2-0046" title="GagelmannN , AyukF , WolschkeC , KrogerN . Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis. Biology of Blood &amp; Marrow Transplantation2017;23(12):2184-91.">Gagelmann 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐(Excluding <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>, Including <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (Included <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>; Excluded <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (Included <a href="./references#CD009159-bbs2-0015" title="BacigalupoA , LamparelliT , MiloneG , SormaniMP , CiceriF , PeccatoriJ , et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplantation2010;45(2):385-91. ">Bacigalupo 2010</a>, excluded </p> <p><a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0008" title="SoifferRJ , KimHT , ChenYB , RybkaW , ArtzAS , BoyerM , et al. Impact of anti-T lymphocyte globulin (ATLG) on immune reconstitution in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT): Results from a prospective randomized double blind phase 3 clinical trial. In: Biology of Blood and Marrow Transplantation. Vol. 23. 2017:S170-S171. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). In: Blood. Vol. 128. 2016. SoifferRJ , KimHT , McGuirkJ , HorwitzME , JohnstonL , PatnaikMM , et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology2017;35(36):4003-11. ">Soiffer 2017</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (Excluded <a href="./references#CD009159-bbs2-0003" title="ChangYJ , WuDP , LaiYR , LiuQF , SunYQ , HuJ , et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. Journal of Clinical Oncology2020;38(29):JCO2000150. [DOI: 10.1200/JCO.20.00150] [PMID: 32650683]No authors listed. Erratum. Journal of Clinical Oncology 2021 Apr 1. [DOI: 10.1200/JCO.20.02641] [PMID: 33780643]ShibusawaM , TanimotoT . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies. Journal of Clinical Oncology 2020 Dec 10. [DOI: 10.1200/JCO.20.02505] [PMID: 33104439]">Chang 2020</a>; <a href="./references#CD009159-bbs2-0004" title="ChoBY , Min GJ , Park SS, Yoon YoonS , ParkS , JeonYW , et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. American Journal of Hematology 2021 Nov 1;96(11):1441-9. [PMID: 34390504]MinGJ , ChoBS , Park S‐S, ParkS , Yahng S‐A, Jeon Y‐W, et al. A phase 3 trial of thymoglobuline for prevention of chronic GVHD intransplantation from an HLA-matched sibling. In: Blood. Vol. 136. 31.May.2021:32. [DOI: https://doi.org/10.1182/blood-2020-139234]">Cho 2021</a>; <a href="./references#CD009159-bbs2-0005" title="DouL , WangL , LiX , LiuY , LiF , WangL , et al. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Medicine (Baltimore) 2021 Feb 26;100(8):1-10. [DOI: 10.1097/MD.0000000000024725] [PMID: 33663084]">Dou 2021</a>; <a href="./references#CD009159-bbs2-0010" title="WuBY , GuoKY , SongCY , ZhangAL , YanDA , YangYL , et al. Decrease of chronic graft-versus-host disease by adding anti-human thymocyte globulin to the conditioning regimen. Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology2004;25(2):91-4. ">Wu 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total no of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>871</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.93 (95% CI 0.77 to 1.13; P=0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.97(95% CI 0.74 to 1.28, P=0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.85 (95% CI 0.63 to 1.13; P=0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG RR 1.2 (95% CI 0.95 to 1.52)</p> <p>Thymoglobulin RR 0.99 (0.84 to 1.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute GvHD</p> <p>Grades 2‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.68 (95% CI 0.60 to 0.79; P = &lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.61(95% CI 0.48 to 0.77; P&lt;0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (95% CI 0.52 to 0.94; P=0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 0.54 (95% CI 0.39 to 0.73)</p> <p>Thymoglobulin HR 0.77 (0.56 to 1.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall Chronic GvHD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR was 0.53 (95% CI 0.45 to 0.61; P&lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR=0.43 (95% CI 0.40 to 0.69; P&lt;0.00001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR=0.54 (95% CI 0.44 to 0.66; P&lt;0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 0.42 (95% CI 0.31 to 0.56)</p> <p>Thymoglobulin HR 0.70 (0.48 to 1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse</p> <p>Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.21 (95% CI 0.99 to 1.49; P = 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.14 (95% CI 0.90 to 1.45; P=0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATLG HR 1.21 (95% CI 0.89 to 1.64)</p> <p>Thymoglobulin HR 0.92 (0.68 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non relapse mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.86 (95% CI 0.67 to 1.11; P = 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.91(95% CI 0.74 to1.13; P=0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.79 (95% CI 0.55 to 1.14; P=0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not available</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>RCT‐ randomised controlled trial, RR Risk ratio, HR Hazard ratio, ATLG Anti‐ T cell Lymphocyte globulin, CI Confidence interval, </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Comparison of contemporary systematic review analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/full#CD009159-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival at 1 year (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Overall survival at 2 years (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.86, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Overall survival at 3 years (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Overall survival (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Overall survival (time to event) ‐ subgroup analysis (ATG‐F low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 ATG‐F ≤ 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.97, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 ATG‐F &gt; 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Overall survival (time to event) ‐ subgroup analysis (Thymoglobulin low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Thymoglobulin ≤ 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Thymoglobulin &gt; 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Overall survival (time to event) ‐ subgroup analysis (Sibling donors vs MUDs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Sibling donors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.71, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 MUDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.81, 1.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acute GVHD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Acute GVHD II to IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 New Subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Acute GVHD II to IV ‐ subgroup analysis (ATG‐F vs Thymoglobulin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.47, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.64, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Acute GVHD II to IV ‐ subgroup analysis (ATG‐F low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 ATG‐F ≤ 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.40, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 ATG‐F &gt; 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Acute GVHD II to IV ‐ subgroup analysis (Thymoglobulin low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Thymoglobulin ≤ 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Thymoglobulin &gt; 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Acute GVHD II to IV ‐ subgroup analysis (Sibling donors vs MUDs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Sibling donors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 MUDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.51, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Acute GVHD III to IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acute GVHD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic GVHD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall chronic GVHD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.45, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Overall chronic GVHD ‐ subgroup analysis (ATG‐F vs Thymoglobulin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.43, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.43, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Overall chronic GVHD ‐ subgroup analysis (ATG‐F low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 ATG‐F ≤ 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.31, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 ATG‐F &gt; 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Overall chronic GVHD ‐ subgroup analysis (Thymoglobulin low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Thymoglobulin ≤ 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.43, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Thymoglobulin &gt; 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.22, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Overall chronic GVHD ‐ subgroup analysis (Sibling donors vs MUDs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Sibling donors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.38, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 MUDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.48, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Limited chronic GVHD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.52, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Extensive chronic GVHD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.25, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic GVHD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Incidence of relapse</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Incidence of relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.99, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Incidence of relapse ‐ subgroup analysis (ATG‐F vs Thymoglobulin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.01, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.79, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Incidence of relapse ‐ subgroup analysis (ATG‐F low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 ATG‐F ≤ 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.01, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 ATG‐F &gt; 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.76, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Incidence of relapse ‐ subgroup analysis (Thymoglobulin low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Thymoglobulin ≤ 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.90, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Thymoglobulin &gt; 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Incidence of relapse ‐ subgroup analysis (Sibling donors vs MUDs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Sibling donors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.89, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 MUDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.93, 1.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Incidence of relapse</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Non‐relapse mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Non‐relapse mortality (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F vs Thymoglobulin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 ATG‐F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.65, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Thymoglobulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Non‐relapse mortality (time to event) ‐ subgroup analysis (ATG‐F low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 ATG‐F ≤ 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 ATG‐F &gt; 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.38, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Non‐relapse mortality (time to event) ‐ subgroup analysis (Thymglobulin low vs high dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Thymoglobulin ≤ 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.47, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Thymoglobulin &gt; 4.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.60, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Non‐relapse mortality (time to event) ‐ subgroup analysis (Sibling donors vs MUDs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Sibling donors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.54, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 MUDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.66, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Non‐relapse mortality (binary) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Non‐relapse mortality regarding GVHD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.20, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Non‐relapse mortality regarding infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.78, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Non‐relapse mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009159-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Graft failure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Graft failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.54, 4.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Graft failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009159.pub3/references#CD009159-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009159.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009159-note-0016">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009159-note-0026">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009159-note-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009159-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009159-note-0021">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD009159-note-0025">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD009159-note-0023">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ms#CD009159-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009159-note-0019">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009159-note-0017">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009159-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009159\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009159\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009159\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009159\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009159\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009159.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009159.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009159.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009159.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009159.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719660444"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009159.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719660447"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009159.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dee296e619371',t:'MTc0MDcxOTY2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 